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Abstract 
Mas oncogene was originally isolated from human epidermoid carcinoma by a 
tumorgenicity assay. Sequence analyse showed that Mas oncogene is a 
membrane protein with seven putative transmembrane segments and it belongs 
to a family member of G-protein coupled receptor. Activation of Mas oncogene 
results in DNA rearrangement of the 5'-upstream non-coding region. 
Transfection studies indicated that Mas either endows an angiotensin response 
or potentiates the endogenous angiotensin response in transfected cells. Over 
expression o^Mas oncogene has been shown to stimulate the mitogen-activated 
protein kinase cascade and leading to an increased expression ofvarious genes, 
such as cyclin, which regulate cellular growth and proliferation. However, Mas 
oncogene shares only 20% of overall sequences identity with cloned 
angiotensin receptor. 
Expression ofa functional ATiA receptor in pancreatoma AR4-2J cells has been 
reported. Co-expression of Mas oncogene and angiotensin receptor in AR4-2J 
cells was confirmed by Western blot analysis using a polyclonal antibody 
against a peptide derived from the putative C-terminal of Mas oncogene and 
full length sequencing of a RT-PCR fragment. Two immunoreactive bands were 
consistently observed with molecular mass of 48 and 62-72 kDa, suggesting 
that Mas protein might be glycosylated. Sequence analysis of the cloned Mas 
oncogene from AR4-2J cells showed that there was two nucleotides change but 
it did not alter the protein sequences. However, Southern blot analysis of Mas 
i 
oncogene did not show any genomic rearrangement in AR4-2J cells. 
InMH3T3 cells that stably transfected withMxs onocogene, morphology ofthe 
cells has been changed from elongated spindle shape to ovoid shape, and the 
cells exhibited lost of contact inhibition. Western blot analysis show that 
expression of Mas oncoprotein was increased in Mas transfected cells when 
compared to the parental cells and mock vector transfected cells. Moreover, by 
using quantitative RT-PCR, mRNA levels of Mas oncogene and angiotensin 
type 1 receptor did increase together mMas stably transfected MH3T3 cells. 
To evaluate the possibility that Mas potentiates angiotensin receptor by up-
regulating the expression of angiotensin receptor via the cis-regulatory 
elements, attempts were made to clone the promoter to a reporter gene (secreted 
form of alkaline phosphate). Expression of the reporter gene will be compared 
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Chapter 1 General Introduction 
1.1 Isolation of Mas Oncogene 
The Mas oncogene was originally isolated from human epidermoid carcinoma 
and identified through a tumorigenicity assay. In the tumorigenicity assay, DNA 
extracted from human epidermoid carcinoma was used to transfect MH3T3 
cells. After two weeks, transfected MH3T3 cells were injected into a nude mice 
and primary tumor was formed. DNA isolated from the primary tumor was used 
to transfect a new batch ofMH3T3 cells again. Transfected cells were injected 
into another nude mice, and secondary tumor was formed. The process was 
continued until the tertiary tumor was formed. DNA was purified from the 
tertiary tumor and a genomic library was constructed. The DNA library was 
probed with total human genomic DNA, and a human gene was identified and 
named as “Mas” (Young et al.，1986). 
This activated Mas gene has the ability to induce foci formation of transfected 
cells in vitro and to induce tumors in nude mice cells within a shorter period 
when compared to the cloned normal Mas gene. Rearrangement of the 5' 
upstream non-coding region of Mas oncogene have been detected in 
transfection assays with genomic DNA from human epidermoid carcinoma. 
However, the parental Mas oncogene in human epidermoid carcinoma did not 
have such DNA rearrangement that was found in the MH3T3 transformant 
(Young et al., 1986). Similar results were obtained in MH3T3 transformants, 
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which were transfected with DNA from human ovarian carcinoma (Van't Veer 
et al., 1988), and human myelocytic leukemia (Janssen et al., 1988). However, a 
tmncated Mas gene comprised only the coding sequences could not transform 
MH3T3 cells. Therefore, rearrangements in the 5，noncoding sequences may 
result in an inappropriate expression of Mas gene. Furthermore, it has been 
reported that in tumorigenicity experiments, Mas sequences have recombined 
with human alphoid DNA (Van't Veer et al., 1993). The alphoid DNA 
originates from the centromere of chromosome three. Sequence analysis of the 
recombination site of a transfectant revealed that a homologous sequence of 
five base pairs (CAGCA) is present in both parental strands and this might 
contribute to the recombinational event. Only in combination with alphoid 
DNA, the Mas sequences were found to be amplified. Morphological changes 
of Nffl3T3 cells induced by Mas amplification could be observed in tissue 
culture. However, there is no direct evidence for an active role of alphoid 
sequence in the process of amplification. And the alphoid sequences is not 
continually required for the growth of tumor. 
Mas encodes a 324 amino acid protein. The protein consists of seven putative 
transmembrane domains suggesting that Mas is an integral membrane protein, 
possibly a family member of G-protein coupled receptors. Moreover, it has 
three putative glycosylation sites at the N-terminus. However, the Mas protein 
does not contain an amino-terminal hydrophobic signal sequence of membrane 
protein. Hence, integration of Mas into the membrane may depend on its 
spontaneously insertion into the membrane or simply due to its hydrophobic 
nature (Young et al., 1986). 
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Mas genes of human and rat share 85% sequence homology in the coding 
regions. They share strong homology in 36 base pairs upstream and 80 base 
pairs downstream from the coding regions. By comparing their protein 
sequence, the rat sequence encodes a protein with 324 amino acid residues 
while that 0fhumanMa5 is 325 amino acid residues long. The difference in the 
length is due to the human Mas protein has one extra amino acid residue in the 
amino-terminal domain which is absent in the xdXMas protein. Moreover, the rat 
and human Mas proteins share 90% amino acid identity overall. Although they 
share only 52% identity in the amino-terminal hydrophilic domains, the three 
potential N-glycosylation sites were conserved (Young et al., 1988). 
In mouse, the Mas gene contains a single exon with 972 nucleotides, which is 
not interrupted by an intron. By comparing the protein sequences of mouse to 
that of rat and human, they shares 97% and 91% of sequence respectively. The 
mouse sequence codes for 324 amino acid residues which is the same as rat 
(Metzger et al., 1995). 
1.2 Distribution of Mas Oncogene 
Distribution of Mas oncogene in normal rat tissues has been studied by 
Northern blot, indicating that Mas is highly expressed in the brain region, such 
as hippocampus and cerebral cortex. Regions like hypothalamus, striatum, 
medulla oblongata, cerebellum and mid-brain are not detected. Moreover, Mas 
mRNA is not detectable in other rat tissues like pancreas, small intestine, heart, 
kidney, muscle, skin and liver (Young et al., 1988). In contrast, RNase 
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protection assay showed that abundant expression of Mas is detected in testis 
and detectable amounts of Mas mRNA is expressed in the kidney and heart, 
while Mas mRNA was not detected in the spleen, the submandibular gland and 
the ovary (Metzger et al., 1995). 
Results from in situ hybridization in rat brain using radiolabeled Mas cRNA 
probes showed that Mas is selectively expressed in the forebrain specifically in 
limbic areas such as dentate gyrus, the CA3 and CA4 areas of the hippocampus, 
the piriform cortex and olfactory bulb (Bunnemann et al.，1990). Similar results 
were reported from Metzger and co-workers (1995), in situ hybridization 
indicates that the highest levels of Mas mRNA are found in the forebrain and in 
the areas of the hippocampus and cerebral cortex. The highly stained region in 
dentate gyrus includes CA3, CA2 and CA1 areas of the gyrus hippocampi, the 
olfactory tubercle, the piriform cortex and the olfactory bulb. Mas mRNA is 
widespread in the cortical areas including the central cortex and the neocortex. 
Moreover, a low amount of Mas mRNA is detected in the medulla oblongata. 
However, Kitaoka and co-workers (1994) reported that the expression of Mas 
was undetected in the medulla oblongata. They demonstrated that expression of 
Mas oncogene was also detected in human retinal pigment epithelium (RPE) by 
both in situ hybridization and RNase protection assay. There was no positive 
signal detected in human adrenal gland. These findings suggest that the Mas-
encoded protein may be a neurotransmitter receptor that is predominantly 
localized in the brain region (Young et al., 1988). 
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1.3 Developmental Expression of Mas Oncogene 
Expression oiMas oncogene in brain is developmentally regulated. It remains 
high in embryogenesis and decrease after birth. Identification of Mas as an 
imprinted gene provides the first evidence that the imprinting plays a direct role 
in the transcriptional regulation of Mas oncogene and suggests a novel 
mechanism in growth control. In mouse, the Mas protooncogene is located on 
the proximal portion of chromosome 17. Allele-specific expression pattern of 
the Mas protooncogene was analysed in mouse developmental stages. mRNA 
genotype analysis revealed a global repression of the maternally inherited allele 
during early fetal development. In between 11 and 12.5 days of gestation, 
expression of paternal allele is found in head, trunk and visceral yolk sac while 
the maternal inherited genes are transcriptionally inactivated. Tissue-specific 
relaxation of the imprinted expression is observed at later stages. In 13.5 days 
of gestation, the paternal allele specific expression of Mas is restricted to heart, 
tongue and visceral yolk sac only. While both the paternal and maternal alleles 
are expressed in brain, liver and trunk. A similar pattern of tissue-specific 
imprinting persisted after birth. Results demonstrated parental imprinting of 
Mas and suggested that the maternally inherited allele is transcriptionally 
repressed in a developmental and tissue-specific manner (Viller et al., 1994). 
Imprinted gene is the transcriptional silencing of one allele of a gene. It depends 
on the sex of the transmitting parent and it play an important role in regulatory 
mechanism in mammalian embryogenesis. (Barlow et al., 1995 Hall et al., 
1997). Genes that are imprinted in mouse tend to imprinted too in human. 
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Examples are IGF2 (Giannoukakis et al., 1993), H19 (Rachmilewita et al., 
1992) and SNRPN (Reed et al., 1994). However, insulin growth factor type II 
(IGF2R) is imprinted in mouse but not in human (Barlow et al., 1991). Since 
both the mouse IGF2R and Mas protooncogene are located on the proximal 
portion of chromosome 17 with less than 300 kb apart (Cebra-Thomas et al., 
1992), there is a possibility thatMo^ is also not imprinted in human. 
In human, Mas protooncogene is located on 6q25.3 — q26 and the physical 
distance ofMas gene and the IGF2R gene is within several hundred kb (Rabin 
et al., 1987). RNAs from different tissues of human fetuses were tested for 
parental allele-specific expression. By sequencing the RT-PCR product, 
biallelic expression is found in brain, intestine, kidney, muscle and tongue. 
Especially in tongue, both alleles are present in DNA and RNA. While for mice, 
Mas gene is paternally inherited in tongue. These results demonstrated that the 
Mas gene is biallelically expressed in three informative fetuses and it is 
apparently not imprinted in human (Riesewijk et al., 1996). 
However, Miller and co-workers reported (1997) that in twenty-one breast 
samples (include malignant, benign and reduction mammoplasties), fourteen of 
them generated Mos-specific RT-PCR products. By sequencing the PCR 
products positive for Mas expression, two out of eight were identified as normal 
samples as heterozygotes. Direct sequencing of corresponding nested RT-PCR 
fragments showed that only one parental allele was expressed in all cases. 




1.4 Study of Mfls-deficient Mice 
Mos-deficient mice has been generated by disrupting the Mas oncogene of 
which the amino-terminal 325 amino acid residues including the six putative 
transmembrane domains was deleted. The resultant transgenic mice lacks Mas 
expression in brain and testis. Obvious developmental abnormalities was not 
observed. The male is fertilizable even with the lost ofMas expression in testis. 
The number, motility and morphology of spermatocytes remained unchanged. 
Also, no difference in drinking behaviour and an intraarterially measured mean 
arterial pressure was observed between the mutant and the wild type mice. 
Immunocytochemical markers were used to characterize specific 
subpopulations of interneurons and principal cells, no obvious alterations could 
be identify in the morphology of the hippocampus and the sub-regions. This 
result suggested that the cytoarchitectonical distribution patterns and the 
delicate neuronal subtypes is not affected by deficiency ofMas. 
With the high expression of Mas in the dentate gyrus which involves in the 
formation ofLTP, depotentiation was employed to study the difference between 
the mutant and the wild type mice. Results show that the Mas deficient mice 
have significant rebound in potentiation after the induction of LTP when 
compared to the control. There is no difference in the paired-pulse depression 
between the two types of mice. By testing the two different groups of mice in 
both the Morris water maze task and anxiety test, the Mas'' mice gives a better 
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performance in the memory retention test and shows less anxiety when 
compared to the control (Walther et al., 1998). 
1.5 Signal Transduction of Mas Oncogene 
The Mas oncogene is predicted to encode a novel G-protein coupled receptor. 
Expression of Mas oncogene leads to activation of phospholipase C and 
indicates that Mas is coupled to the Gaq/n (Hardwick et al., 1992, McGillis et 
al., 1989, Poyner et al., 1990). However, the signal transduction pathways 
activated by Mas oncogene leads to cell transformation have not been 
determined. Recent research showed that the signaling and transformation of 
Mas oncogene required a small GTP-binding protein Rac (Zhon et al., 1998). It 
is noted that the foci of transformed MH3T3 cells caused by Mas oncogene is 
similar to those caused by constitutively activated Rho and Rac but distinct 
from the ones caused by the activated Ras. Foci formed by activated Ras is 
large and contained highly refractile spindle-shaped cells, while foci formed by 
activated Rho and Mas were densely packed nonrefractile cells. Moreover, 
focus-forming activity by Mas was much greater than Rac and Rho. At present, 
more than 11 distinct mammalian Rho family proteins have been identified. The 
Rho protein functions as a GDP-GTP binary switch, and they can cycle between 
an active GTP-bound form and inactive GDP-bound form. Rho proteins are 
activated by guanine nucleotide exchange factors, and inactivated by GTPase-




Studies from the immunofluorescence analysis in the stably transfected MH3T3 
cells with activated Ras, Rac and Mas showed that both Mas and activated Rac 
cause stress fibers, focal adhesions and membrane ruffling. On the other hand, 
stable transfected MH3T3 cells with activated Ras only causes membrane 
ruffling but do not causes stress fibers and focal adhesions. Moreover, both Mas 
and activated Rac induce lamellipodium formation�Coexpression of activated 
Rho family protein with activated Raf in MH3T3 cells causes a synergistic 
enhancement of focus forming activity. Results of foucs forming activity and 
immunofluorescence studies suggested that Mas may mediate through the 
signaling pathway of Rac. However, the signaling pathway of Mas 
transformation is not so simple because Mas induces a reproducible but weak 
activation of ERK2 which does not occur in the signaling pathway of Rac. 
Therefore, there is a possibility that Mas may also activate through the Rac 
independent pathway. The current hypothesis is that Mas is mediated through 
Raf, MEK and protein kinase cascade to perform transforming activity (Zohn et 
al., 1998). 
1.6 Other Family Member of Mas Oncogene 
Most G-protein coupled receptors share the common features that they contain 
one or more potential N-linked glycosylation sites near the amino terminus, lack 
the amino-terminal signal peptide, have several conserved amino acid residues 
and the protein are encoded by a single exon. By screening the rat genomic 
library with a 159 nucleotide probe which encodes the transmembrane segment 
of the Ml muscarinic receptor in low stringency, a previously unknown member 
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of G-protein coupled receptor RTA was identified. Sequence analysis ofRTA 
indicated that it contains a single exon and encodes for a protein with 343 
amino acid residues. By resolving it in the SDS-PAGE, the apparent molecular 
size was shifted from 36 kDa to 38 kDa. This is suspected due to the presence 
of an N-linked glycoslation site near the amino terminus of RTA. Mas and 
RTA share 34% identity in a region of 295 amino acid residues while RTA 
shares only 29% identity to the muscarinic acetylcholine receptor with 198 
amino acids overlap. Moreover, RTA protein also contains seven putative 
transmembrane segments, lacks amino terminus signal peptide and contains a 
single gene copy. Therefore, it is predicted that RTA is a family member of G-
protein coupled receptor. RTA mRNA is highly expressed in smooth muscle 
like vas deferens, uterus, large and small intestine, aorta and brain region 
especially in cerebellum. However, RTA is weakly expressed in liver, kidney, 
lung and adipose (Ross et al.，1990). 
A third member of Mas related gene was obtained from a human genomic 
library with low stringency screening by using Mas cDNA as probe. Sequence 
analysis showed that a positive clone called 'Mrg' contains an open reading 
frame of 1134 nucleotides encoding a 378 amino acid protein with a calculated 
molecular mass of 42 kDa, and it displays a high homology with Mas (46%). 
Evidence showed that Mrg contains seven hydrophobic regions of 16 to 27 
amino acids, lacks signal peptide sequence and intron within the coding region. 
Moreover, Mrg contains two potential N-glycosylation sites, has five out of 
twenty conserved cysteines residues within hydrophobic segments or 
intracellular loops and it also contain highly conserved residues that are also 
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found in G-protein coupled receptors (Leull5, Aspll9, Argl71, Prol78, 
Trpl98, Phe272, Pro278, Asn309, Pro310, lle312, and Tyr313). Mrg shares 
35% sequence identity with Mas protein over 290 amino acids overlap and 
share 84% sequence identity in 26 and 25 amino acids at the beginning of the 
second intracellular loop and the beginning of intracellular C-terminal segment, 
respectively. Other than that, sequence of theMr^ third intracellular loop has no 
homology with either the known peptidergic receptors or with other members of 
Mas subgroup. In Northern blot analysis，Mrg product cannot be detected in 
adult human normal tissues (adrenal gland, liver, vascular smooth muscle and 
kidney) and rat tissues (brain, hypothalamus, cerebellum, uterus, testis, heart, 
aorta, lung, adrenal gland and liver) (Monnot et al., 1991). 
1.7 Mas and Angiotensin Receptor 
Similarities of the Mas oncogene to known receptors suggested that it might 
encode a receptor with growth control activities with its mechanism and 
physiological stimulant remain unknown. Molecular cloning of the bovine 
substance K receptor (Masu et al., 1987) demonstrated that sequence homology 
between Mas and the substance K receptor. Mas oncogene has high sequence 
homology with substance-K receptor and therefore, it was predicted that Mas 
encodes a peptide receptor which is involved in the inositiol lipid signaling 
pathway via phospholipase C (Hanley et al., 1987). 
Believing that the Mas oncogene product encodes a receptor, a wide range of 
peptide was added to the Mas stably transfected neural cell line NG115-401L to 
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screen for the ligand oiMas by using intracellular calcium as indicator. In this 
experiment different peptides include AVP, bombensin, VIP and ANG II were 
added. None of the peptides can stimulate the response except ANG 11. The 
response is similar to the bradykinin which acts as a positive control (Hanley et 
al., unpublished data). 
Injection oiMas mRNA into oocytes gives out an inward current in response to 
bath-applied angiotensins I (ANG I), II (ANG II) and III (ANG III). The 
angiotensin response is in a dose dependent manner that Mas product has higher 
potency to ANG III then to ANG II while the least to ANG 1. Moreover, such a 
response can be reversibly blocked by a board-spectrum substance P antagonist, 
[D-Argi, D-Prc)2, D-Trp^'^, Leu^^]substance P, but not by angiotensin antagonist 
;Sar\ Val^, Ala^]AI and [Sar\ Val^]-AIL However, when using the suggested 
antagonists of angiotensin instead of substance P, only weak agonist activity 
was shown. Furthermore, there is no response in bath application ofbradykinin. 
To fiirther analyse the function of Mas, the neural cell line NG115-401L was 
stably transfected with the Mas gene to analyse the angiotensin sensitivity by 
using intracellular calcium indicator. Results showed that the Mas stably 
transfected cell line give a dose-dependent response of intracellular calcium 
concentration with ANG III > ANG II > ANG I. This ranking is the same as 
that found in oocyte. Results from the transfection study suggested that Mas 
oncogene is a fiinctional angiotensin receptor (Jackson et al., 1988). 
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By using monosepecific antipeptide antibodies which is raised from the 
intracellular C-terminal tail of human Mas, a protein (45 kDa) was detected in 
Mas transfected cells which is co-localized with a protein band but can be 
chemically or photochemically cross-linked to [^]-labeled angiotensins in 
Western blot analysis (Hanley et al., 1990). 
Transient Mas expression in mammalian COS cells leads to an increase in 
intracellular calcium levels in response to angiotensin stimulation (McGillis et 
al., 1989). Temporal changes in [^H] inositol-labeled lipids and phosphates 
were examined in the Mas stably-transfected NG15-40L-C3 neuronal cell line 
clone. Angiotensin stimulates the expected production of the second messenger, 
authentic inositol-l,4,5-trisphosphate (Poyner et al., 1990). 
Moreover, the angiotensin stimulates an elevation of intracellular calcium levels 
in Mas transfected cells by discharge from calcium stores in a dose-response 
relationship which is very similar to that of stimulation of current response in 
mciroinjected oocytes (Jackson et al., 1988). Furthermore, angiotensin also 
causes a sustained activation of protein kinase C in Mas transfected cells 
(Jackson et al., 1989). 
Mas oncogene was shown to exert some effect on cellular responses to 
angiotensin type I receptor. By comparing the response of parental cell line and 
Mas transfected cell line to the added angiotensin I I , only the Mas transfected 
cell line gives similar response to epidermal growth factor which is used as a 
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positive control. The result suggested that Mas oncogene can enhance the 
responses ofendogenous ATi receptor (Ambroz et al., 1991). 
1.8 Angiotensin Receptor 
1.8.1 Classification of Angiotensin Receptor 
Angiotensin receptor is divided into 2 main types , ATi and AT2. Type 1 
angiotensin receptor (ATi) is further divided into 2 subtypes, which is type lA 
and type lB receptors. However, there is only one ATi receptor in human (Su et 
al.，1994). Angiotensin type I receptors mediate most of the known functions of 
angiotensin. The function of angiotensin type 2 receptors is not well known but 
it may play an important role in fetuses development. 
Pharmacologically, ATi receptors can be distinguished from AT2 receptors by 
its selective affinity to biphenylimidazoles like losartan while ATi receptors is 
insensitivity to tetrahydroimidazopyridines such as PD123177. Also ATi 
receptors have higher binding affinity to ANGI and ANGII while for ANGIII is 
the least. Moreover, displacement of antagonist binding by agonist ANG II is 
shallow, which suggested that ATi receptors only have homologous state for 
antagonist binding while they have heterogeneous states for agonist binding. 
Therefore, the pharmacological feature of agonist binding to ATi receptors is 
predicted to be similar to a binary switch that the affinity state is 
interconvertible by guanine nucleotide (Griendling et al., 1990). For 
mammalian ATi receptors, other than the two subtypes of ATiA and ATie, the 
14 
Chapter 1 
third type termed ATic was isolated from the rat placenta. The ATic receptors 
have only 82% sequence homology to ATie while they have 90% sequence 
homology to ATiA receptors (Hahn et al., 1993). 
Both ATiA and ATiB receptor are fairly expressed in spleen, liver and kidney. 
Angiotensin ATiA receptor is predominately expressed in vascular smooth 
muscle, heart, lung , liver and brain. However, the majority expression of ATie 
receptor is detected in pituitary and adrenal glands. In signal transduction, 
ligand binding to ATi receptor regulates effectors via G-protein and it seems 
that the ATi receptors are coupled to multiple effectors rather than a single 
effector. 
Angiotensin type II receptor displays an extreme by low binding affinity to 
biphenylimidazoles but have high affinity for tetrahydroimidazopyridines when 
compared to ATi receptor. The binding affinity of AT2 receptor to ANG II is 
similar to that of ATi receptor. In regard to the binding of ANG III, AT2 
receptor is slightly lower than that of ATi receptor. However, the agonist 
binding affinity 0fAT2 receptor is increased by dithiothreitol (Chiu et al., 1989, 
Speth et al., 1990 and Chang et al., 1990). 
1.8.2 Cloning of Angiotensin Receptors 
The cDNAs for the angiotensin II type lA receptors were cloned from rat 
vascular smooth muscle cells (Murphy et al., 1991) and bovin adrenal zona 
glomemlosa cells (Sasaki et al., 1991). In rat and mouse, the ATiA and ATm 
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subtypes share about 94% in overall sequence identity with the main difference 
present in the carboxyl-terminal region of the protein. The ATiA receptor has 
two additional putative protein kinase C phosphorylation sites which are absent 
in ATiB receptor. Moreover, the ATiB receptor lacks a possible palmitoylation 
site. 
A complementary DNA encoding a bovine adrenal angiotensin II - receptor 
reveals that the polypeptide is encoded by an open reading frame consisting of 
359 amino acid residues with a relative molecular mass of 41,093. The encoded 
protein has a seven-transmembrane domain but shares only about 20 - 30% 
sequence identity with those of other G protein-coupled receptors. However, it 
shares only 20% of sequence identity in the transmembrane region with human 
Mas oncogene product. Subfamily member of G-protein coupled receptor such 
as muscurinic acetylcholine receptors and adrenergic receptors share at least 
35% sequence homology. Therefore, the hypothesis that Mas encodes an 
angiotensin receptor need further investigation. The cloned angiotensin receptor 
encodes a protein of 359 amino acid residues with a transmembrane topology 
similar to that of other G-protein coupled receptor. Transient transfection in 
Cos-7 cells with cDNA expressed specific and high-affinity binding sites for 
angiotensin II, angiotensin II antagonist, and a non-peptide specific antagonist 
for type-1 receptor. An increase in intracellular Ca�+ and inositol-1,4,5-
triphosphate in the transfected Cos-7 cells is observed in response to 
angiotensin II or angiotensin III, suggesting that this receptor is type-1 for 
angiotensin II (Sasaki et al., 1991). 
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The AT2 receptor was cloned from a rat fetal cDNA library and from 
pheochromocytoma PC12W cells (Kambayashi et al., 1993 and Mukoyama et 
al., 1993). Like ATi receptor, it belongs to a seven-transmembrane domain 
receptor encoding for a 363 amino acid with a molecular mass o f41 kDa. By 
comparing the protein sequence with ATi receptor, they share only 34% in 
overall identity. By analysing the structure of ATi and AT2 receptors, the ATi 
has only 3 consensus N-glycosylation sites while AT2 receptor has five potential 
glycosylation sites. When the protein product from AT2 receptor was treated 
with N-glycosidase, the molecular mass was shift from 80 kDa to 40 kDa. 
1.9 Expression of Angiotensin Receptor 
1.9.1 Physiological Factors 
Angiotensin II is a multifunctional hormone that mediates its physiological 
action through the cell surface receptors. Angiotensin II is the active product of 
the renin-angiotensin system. It influences systemic blood pressure by 
triggering a cascade of physiologic changes resulting in the expansion of 
extracellular volume and contraction of vascular smooth muscle (Peach et al., 
1990). 
The renin-angiotensin-aldosterone system (RAS) plays an important part in the 
maintenance of sodium homeostasis of an organism. RAS activity is regulated 
by the amount of salt intake which then determines not only the secretion rate of 
renin from the kidneys, but also the expression of ATi receptor. As ANG II 
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increases vascular resistance, salt reabsorption in the kidney is increased 
directly by tubular reabsorption, and indirectly by the stimulation of aldosterone 
production�Salt appetite is increased by the action on the brain mediated 
through the ATi receptor. The efficacy ofRAS is determined by the availability 
of ATi receptor and the concentration of circulating ANG II. Sensitivity of 
aldosterone production towards ANG II will be increased when animals are fed 
with low salt diet which in turn increases the number of ATi receptor binding 
sites in the adrenal zona glomerulosa. Also, upregulation of angiotensin 
receptor in low salt diet was observed in the whole kidney (Du et al., 1995, 
Wang et al., 1995). To investigate the effect of different salt diet in ATi 
receptor expression, three groups of Sprague-Dawley rats were feed with low 
salt (0.2 mg/g), normal salt (6 mg/g) and high salt (40 mg/g) diet for couples of 
days. Results showed that high salt diet (40 mg/g) does not significantly 
enhance or suppress the expression of ATi receptor mRNA. However, in low 
salt diet (0.2mg/g), the expression of ATi mRNA does increased. Since ATiA 
receptor is predominantly expressed in liver, lung, heart and total brain while 
ATiB receptor is predominantly expressed in the adrenal gland and detectable in 
the kidney, the proportion of ATiA to ATie receptor in different tissues will 
have different ratio. In high salt diet, the proportion of ATiA to ATie did not 
alter in liver, adrenal gland and kidney. However, in liver low salt diet (0.2 
mg/g) leads to downregulation of ATiA receptor while the expression of ATis 
receptor remains unchanged, which leads to lower ratio of ATiA to AJm 
receptor in liver. In adrenal gland, low salt diet leads to a significant increase of 
ATi mRNA, but lower the ratio of ATiA to ATiB receptors. In kidney, low salt 
intake decreases ATi receptor mRNA and decrease the ratio of ATiA to ATiB. 
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In lung, low salt intake leads to decrease of ATi mRNA and decrease of the 
ratio ofATiA to ATm mRNA. However, the effect of salt intake in expression 
of ATi receptor is transient. For salt intake more than 3 weeks, the expression 
of ATi receptor returns close to the original level. The findings suggested that 
oral intake of salt will alter the expression of ATi receptor gene in tissue 
specific manner. The response of ATiA receptor to the rate of salt intake is 
positive while ATiB receptor gives a negative response (Schmid et al., 1997). 
1.9.2 Cis-regulating Elements 
1.9.2.1 Organization and Regulatory Elements of ATi Receptor 
Genomic sequence of rat ATi receptor consists of three exons. Two of the 
exons encode 5’ untranslated sequence while the third exon encompasses the 
entire coding region. By analysing the 5' upstream region of the genomic DNA 
sequence, several sequence motifs are found. They include a putative cap signal 
in the 5' upstream region of the start site, a TATA box sequence which is 
located at 36 nucleotides 5' upstream to the start site, a GC box which is located 
at 60 nucleotides 5，upstream to that of the TATA box sequence. Moreover, 
the exons also contain 16 repeats of the dinucleotide AG. This sequence 
probably will show length plymorphisms between different strains of rats. Such 




The transcriptional activity of rat ATiA receptor was studied by fusing the 
various 5, deletion mutant of the receptor gene to the upstream region of 
chloramphenicol acetyltransferase (CAT) gene. The transcriptional assay was 
performed in three different cell types which include the rat pheochromocytoma 
cells (PC12), glial cells and the rat vascular smooth muscle cells (AlO). 
Functional analysis of the 5’ flanking region of the ATiA receptor revealed that 
it has at least three positive regulatory elements P1 (-560 to 489), P2 (-331 to — 
201), P3 (-201 to -61), and one negatively regulatory element (-489 to -331) 
located in the 980 base pairs upstream of the sequences. The regulatory element 
o f P l was active in the three cell types but P2 was only active in glial and PC12 
cells. Moreover, competitive inhibition experiments using the P2 fragment 
shown that cellular trans-acting factor for the P2 element is indeed functional 
only in these two cells. However, negative regulatory element (N1) only 
function in PC12 cells and competitive inhibition experiments confirmed that 
trans-acting factor that interact with the inhibitory cis-acting element present 
only in PC12 cells (Murasawa et al. 1993). 
1.9.2.2 Expression of ATiA Receptor was Induced by AP-1 and GATA-4 in 
Pressure Overload Model 
Angiotensin II is a multi-hormone which mediates the hypertrophy of 
mammalian cardiac muscle cells and is a chemical mediator of stretch induced 
cardiomyocyte hypertrophy. Pressure overload (P0) increases the expression of 
ATiA receptor by 1.6 folds when compared to the controls. ANG II is released 
from ventricular cardiomyocyte granules and exert effect on cardiac myocyte. 
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Angiotensin initiates alterations in gene expression and result in hypertrophic 
growth of myocardium and the effect is mediated through ATiA receptor. In 
order to determine the increased ATiA receptor activity is mediated through 
angiotensin II, an angiotensin-converting enzyme inhibitor (captopril) was used 
to treat the animals both before and along with the period of aortic coarctation 
(CoA). Captopril can significantly reduce the arterial pressure in animal was 
subjected to period of aortic coarctation and reduced the ATiA receptor activity 
by 62% as compared to 50% in control group. For isolated neonatal cardiac 
myocytes transfected with ATiA receptor gene in the absence or presence of 
angiotensin II, expression of ATiA receptor is increased by 1.6 folds in the 
presence of angiotensin II treatment. 
The transcriptional response to stretch from ATiA receptor or by angiotensin II 
treatment will cause a rapid induction of the immediate early genes such as c-
fos which results in accumulation of c-fos protein. And the c-fos protein 
associated with jun family members to constitute the AP-1 activity. Consensus 
AP-1 and GATA binding sites located form -397 to -381 base pair and from 
-282 to -277 base pair are noted in ATiA receptor promoter. By mutating the 
consensus binding sites for AP-1 and GATA transcription factors, effect of 
pressure overload was abolished. However, AP-1 site will not be active while 
GATA is mutated and vice versa. Results suggested that both the AP-1 and 
GATA DNA recognition sequences in the ATiA receptor promoter are 
important for PO-induced response and they must be associated with each other 
to take action. Results from gel shift mobility presented that other trans-acting 
factors were associated with the AP-1 and GATA sites. They include c-Fos (4), 
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c-Fos (4-10-G), c-Jrni/AP-lQSO, Jun_A7) and JunD(329). In sequence-
specific DNA binding activities, GATA-5 and GATA-6 interact with the a -
MHC site (Herzig et al., 1997). 
1.9.2.3 ATiA Receptor Reveals Three Glucocorticoid Responsive Elements 
A possible way of glucocorticoid-induced hypertension has been suspected to 
be the enhancement of vascular sensitivity to ANG II. Sequence analysis 
showed that the ATi receptor contain three glucocorticoid responsive elements 
in the promoter region. They are located in -870 to -856 base pair (GRE 1)，-
770 to -756 base pair (GRE 2) and -407 to -378 base pair (GRE 3) from the 5’ 
upstream region of exon 1. GRE III overlaps with an AP-1 recognition 
sequence (-387 to -381) (Uno et al., 1994). 
The promoter activity assay demonstrated that among the three GRE elements, 
only the GRE2 confers the glucocorticoid sensitivity on the ATiA receptor 
gene. However, the GRE2 motif located from -770 to -756 has three base pairs 
mismatch at -770, -760 and -759 when compared to a consensus GRE motif. 
Also, the GRE motif located from -559 to -545 has five base pair mismatch 
sequence located at -558, -557, -556, -555 and -547 (Murasawa et at., 1995). 
1.10 Signal Transduction of Angiotensin Receptor 
Vascular angiotensin receptor (Alexander et al., 1985) transmits their 
extracellular signals to the cell interior by a second messenger pathway 
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involving the stimulated breakdown of inositol phospholipids by activated 
phospholipase C (Berridge et al., 1987). 
Recent studies was shown that ATi receptor can activate multiple signal and 
transduction pathways by coupling to heterotrimeric G proteins. These signal 
transduction pathway include inositol phosphate production (Sasaki et al., 1991 
Ohnishi et al., 1992), intracellular calcium mobilization (Sasaki et al., 1991 
Ohnishi et al., 1992), activation of protein kinase C (Tsuda et al., 1990), 
inhibition of adenylate cyclase (Ohnishi et al., 1992), activation of mitogen-
activated protein cascade (Molly et al., 1993) and induction of the immediately 
early genes such as c-fos (Sadoshima et al., 1993). Previous studies using site-
directed and deletion mutagenesis demonstrated that several amino residues 
located between the second and third intracellular loop play an important role in 
ATi receptor coupling to Gq (Asp-74 in the second and Tyr-292 in the seventh 
transmembrane domain). However, which intracellular loops of ATi receptor is 
required to couple to G-protein has not been determined. To identify the 
fixnctional intracellular domain of ATi receptor, AT1/AT2 receptor chimera was 
constructed and expressed in CHO cells by monitoring the expression level of 
c-fos gene and calcium ion mobilization (Wang et al., 1995). The chimera 
Clwas constructed by swaping the intracellular loops 2 of ATi to AT2. For 
chimera C3 the cytoplasmic tail of ATi was replaced by cytoplasmic tail of 
AT: Chimera C2 was constructed by substituting the amino acid residues 
located from 219 to 236 of ATi receptor to residues from 141 to 159 
(intracellular loop 3) of AT2 receptor. Chimera C1 and C3 are able to mediate 
angiotensin II-induced c-fos expression. However, chimera C2 was unable to 
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induce c-fos expression in CHO cells. The failure of the chimera C2 responds to 
angiotensin II results from inability of this receptor to activate the Gq protein 
while others bind Gq with an affinity comparable to the wild-type (Wang et al., 
1995). 
To further evaluate whether the intracellular loop 3 alone is sufficient to confer 
Gq-mediated signaling to angiotensin receptor, a C10 chimera was constructed 
by replacing amino residues located from 235 bp to 256 bp of AT2 receptor with 
the corresponding amino residues located from 219 bp to 240 bp of ATi 
receptor. Binding of angiotensin to Chimera C10 is lower than that of the wild 
type ATi and AT2 receptors. However, in co-transfection study using C10 
chimera with /os"-luciferase reporter gene in CHO cells, a high basal value of 
/os-luciferase activity was observed which suggests that a constitutive 
activation of the fos promoter in a ligand independent manner. This suggestion 
was supported by the results of co-transfection of different amounts of wild type 
and C10 chimera. Results of chimera study suggested that the N-terminal 
portion and the C-terminal portion of the second extracellular loop which is 
adjacent to the fifth transmembrane region of the receptor are critical for 
receptor signaling, while amino acids from 226 to 231 in the intermediate 
portion of intracellular loop 3 are not essential for Gq signaling by ATi receptor 
(Wang et al., 1995). 
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1.11 Aim of Project 
The aim of the project is to evaluate whether the increase in angiotensin 
response in Mas over expressed cells is mediated by up-regulating the 




Chapter 2 Mas Oncogene in AR4-2J cells 
2.1 Introduction 
Previous studies from our laboratory have shown that pancretoma AR4-2J cells 
expressed a functional ATiA receptor which mediates angiotensin-stimulated 
amylase release (Yiu et al., 1999). In contrast, in vitro perfusion of rat pancreas 
demonstrated that CCK-8 and carbachol elicit amylase but not angiotensin II were 
released. The results suggest that functional angiotensin receptor is not normally 
expressed in rat pancreas. 
Since Mas oncogene has been reported to endow or to potentiate endogenous 
angiotensin response, study was undertaken to evaluate the expression of Mas 
oncogene in AR4-2J cells and to reveal its biochemical characteristics. 
26 
Chapter 1 
2.2 Materials and Methods 
2.2.1 Materials 
2.2.1.1 Reagents 
TrizolzoL，DNAzoL, Dulbecco's modified Eagle medium (DMEM), Dulbecco's 
phosphate-buffered saline (PBS), fetal calf serum (FCS) penicillin and 
stereptomycin were obtained from Gibco-BRL. Phenol:chloroform:isoamyl alcohol 
and sodium acetate (2M pH 4.0) were obtained from Promega. DIG Easy Hyb 
buffer, DIG block and wash buffer set, DIG-ll-dUTP, anti-digoxigen-AP 
conjugate and CDP-Star™ were obtained from Boehringer Mannheim. While 
nynon membrane, T7 Sequenase version 2.0 DNA sequencing kit and [a-^^S]dATP 
were obtained from Amersham. dRhodamine terminator cycle sequencing kit and 
reagents were obtained from PE Applied Biosystem. 
2.2.1.2 Enzymes 
All DNA primers, dNTP, Taq T4 DNA ligase, SuperScript™ E kit and Taq DNA 
polymerase were obtained from GibcoBRL. Restriction endonucleases including 
Bgl II, EcoR V, Kpn I, Nco I, Not I, Pvu I, Pst I, Xho I and Xmn I were obtained 
from New England BioLabs fNEB). Restriction enzymes including BamH I, EcoR 
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I, Hind III Xba I, and DNA polymerase I large (Klenow) fragment were obtained 
from Promega. 
2.2.1.3 DNA Purification Kits 
QIAquick gel extraction kit, Qiagen plasmid midi and maxi kits were obtained 
from Qiagen. Wizard™ plus minipreps DNA purification system and Geneclean 
II® kit were obtained from Promega and BIO 101 Inc., respectively� 
2.2.1.4 Materials and Antibodies for Western Blot 
Nitrocellulose and AP-Goat anti-rabbit IgG (H+L) were obtained from Schleicher 
& Schuell and Zymed，respectively. 4-Nito blue tertazolium chloride and X-
phosphate/5-bromo-4-chloro-3-indolul-phosphate were obtained from Boehringer 
Mannheim. Prestained protein standards (12kDa — 98kDa), and Mini-protein® II 
cell were obtained from Bio-Red. Semi-dry blotter was obtained from Owl. 
2.2.1.5 Others 
The lkb DNA ladder markers and agarose (electrophoresis grade) were obtained 
from Gibco-BRL. The 100 bp ladder markers was obtained from Pharmacia 
Biotech. The pBluescript® n SK vector was obtained from Stratagene. Ampicillin 
was obtained from Sigma. 
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2.2.2 Restriction Enzyme Digestion 
Plasmid DNA was mixed with appropriate restriction enzyme and digestion buffer, 
provided by the manufacturer, and then incubated at 37 ^C for 2 hours. For 
genomic DNA, reaction mixture was incubated for 6 hours. About lU of enzyme 
per jj^ g DNA was used. DNA fragments were obtained after separation by agarose 
electrophoresis. 
2.2.3 Agarose Gel Electrophoresis 
Agarose was dissolved in TBE buffer and ethidium bromide (lM-g/ml) was added. 
After the gel completely solidified, markers and DNA samples in lx DNA loading 
buffer were loaded into the wells. The gel was then run under constant voltage 
(120V). For DNA with size larger then 3kb, 0.7 % agarose gels were used while 
DNA with size smaller than 3kb, 1% agarose gels were used. 
2.2.4 DNA Extraction and Purification 
The gel was examined under ultraviolet light and the desired DNA fragment was 
excised from the gel. QIAquick Gel Extraction Kit was used to purify those DNA 
fragments with size between 500 bp up to 10 kb. The DIG labelled DNA fragment 
was purified with the Geneclean II® Kit. The extraction processes were according 
to the instruction provided by the manufacturers. 
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2.2.5 Plasmid Vector Modification and DNA Ligation 
For TA ligation, the plasmid vector was blunt end cut with restriction 
endonucleases. The plasmid was mixed with a 10x Polymerase Chain Reaction 
(PCR) buffer, magnesium chloride (MgCl2) and dTTP each was in a final 
concentration of 2 mM, and 5U of Taq polymerase. The reaction mixture was 
incubated at 72 °C for 2 hr. The product was purified by QIAquick Gel Extraction 
Kit. DNA insert and vector were mixed together in 5 to 1 molar ratio to make up a 
reaction mixture containing about l^ig DNA, T4 DNA ligase ( lU per jug DNA) and 
ligation buffer (lx in final concentration) in a final volume of 20 i^l. The reaction 
mixture was incubated at 16 °C overnight. 
For blunt end ligation, plasmid vector was blunt end cut with restriction 
endonucleases. DNA insert and vector were mixed together in 5 to 1 molar ratio to 
make up a reaction mixture containing about l^ig DNA, T4 DNA ligase ( lU per i^g 
DNA) and ligation buffer (lx in final concentration) in a final volume of20 i^l. The 
reaction mixture was incubated at 16 °C overnight. 
For directional cloning, the plasmid and DNA insert were digested with compatible 
restriction endonucleases. DNA insert and vector were mixed together in a molar 
ratio o f3 to 1 to make up a reaction mixture containing about l^ig DNA. T4 DNA 
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ligase (lU per [xg DNA) and ligation buffer (1 x final concentration) in a final 
volume of20 p l The mixture was incubated at 16 ^C overnight. 
2.2.6 Bacterial Transformation 
Bacteria E.coli (XL1 blue, XL1 blue MR, DH5a or HB 101) culture (20 ml) 
reaching early mid-log phase was collected by centrifiagation at 1,200 x g for 5 min 
and then resuspended with 10 ml ice cold O.lM calcium chloride. Cells were 
centrifugated and resuspended twice in 10 ml ice cold O.lM calcium chloride. Cells 
were recovered by centrifigation (1,200 x g) and resuspended with 2 ml ice cold 
0. lM calcium chloride. DNA about 1 i^g was added to a tube of competent cells 
(100 i^l). After mixing, the tube was kept in ice for 30 min. and then heat shock at 
42 ^C for 2 min. After that, 500 jji Luria-Bertani (LB) medium was added to the 
tube which then incubated at 37 ^C for 1 hour. The cells were spun down and 500 
U^ LB was removed. The remaining 100 i^l LB was used to resuspend the cell pellet 
and then all the cells were plated onto a LB plate with selective antibiotics (100 
mg/ml Ampicillin). The plate was inverted and incubated at 37 °C overnight. 
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2.2.7 Preparation ofPlasmid DNA 
2.2.7.1 Minipreps 
Each single colony of transformed cells was inoculated in a tube containing 3 ml 
LB with selective antibiotics (100 mg/ml ampicillin) and then incubated at 37^C 
overnight with shaking at 230 rpm. Overnight culture (1.5 ml) was transferred into 
a 1.5 ml eppendorf centrifuge tube and pelleted at 15,800 x g for 30 seconds. 
Supernatant was decanted and the cells pellet was resuspened with 200 jiil Cell 
Resuspension Solution (50mM Tris-HCl, pH 7.5, lOmM EDTA and lOO i^g/ml 
RNase A). Cell Lysis Solution (0.2M NaOH and 1% SDS; 200 i^l) was then added 
and mixed by gently inverting the tube several times. Afterwards, Neutralization 
Solution (2.55M KOAc, pH 4.8; 200 i^l) was added and mixed by inverted the tube 
several times. The tube was centrifuged at 15,800 x g for 5 min. The cleared 
supernatant was transferred to a new eppendorf centrifuge tube with 1 ml of the 
Wizard™ Minipreps DNA purification Resin. For each miniprep, one Wizard™ 
Minicolumn was set by attaching with a Syringe Barrel to the Luer-Lok® extension 
ofeach Minicolumn. The Resin/DNA mixture was transferred into the barrel ofthe 
Minicolumny^Syringe assembly, and syringe plunger was inserted to push the slurry 
into the Minicolumn. Unbound DNA was removed by adding 2 ml of Column 
Wash Solution (200mM NaCl, 20mM Tris-HCl, pH 7.5 and 5mM EDTA). 
Afterwards, the minicolumn was transferred to a new 1.5 ml eppendorf centrifuge 
tube and 50 i^l of TE Buffer (lOmM Tris-HCl, pH 7.5 and lmM EDTA) was 
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added. Finally, the DNA was eluted by centrifiige the whole set up at 15,800 x g 
for 1 min. 
2.2.7.2 Midipreps and Maxipreps 
For Midi Prep, overnight transformed bacteria culture (1 ml) was added to 300 ml 
LB with 100 ^ig/ml ampicillin and incubated overnight with continuous shaking at 
a speed of230 rpm at 37 °C. For Maxi prep, similar procedures as Midi prep except 
3 ml of the transformed bacteria culture was added to 750 ml LB. The overnight 
culture was split into two 250 ml centrifuge bottles while three 250 ml bottles for 
Maxi prep. Then the cells were pelleted down at 7,520 x g for 10 min. For each 
bottle, after the supernatant was decanted, the cell pellet was resuspended with 4 ml 
P1 solution (50mM Tris.Cl, pH 8.0, lOmM EDTA and 100 i^gAnl RNase A) and 4 
ml P2 solution (200 mM NaOH, 1% SDS). Afler incubation at room temperature 
for 5 min, 4 ml of chilled P3 solution (3.0 M potassium acetate, pH 5.5) was added 
and contents from all three bottles were transferred to two 50 ml Nalgene 
centrifuge tubes. For Maxi prep, 10 ml o f P l solution and P2 solution was used for 
each bottles instead. Having placing on ice for 20 min, the tubes were centrifuged 
at 15,000 rpm for 30 min at 4 � C . Qiagen-tip 100 or 500 column was first 
equilibrated with 4 ml or 10 ml QBT buffer (750 mM NaCl, 50 mM MOPS, pH 
7.0，15% isopropanol and 0.15% Triton® X-100), respectively. Then all of the 
supernatant in the centrifuge tubes was loaded to a column. Afler the supernatant 
has passed through, the column was washed twice with 10 ml or 30 ml QC buffer 
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(lMNaCl, 50 mM MOPS, pH 7.0 and 15% isopropanol), respectively. Finally, 5 
ml or 15 ml QF buffer (1.25 M NaCl, 50 mM Tris, Tris.Cl, pH 8.5 and 15% 
isopropanol) was used to elute the plasmid DNA out from the column. The solution 
containing the plasmid DNA was mixed with 3.5 ml or 10 ml isopropanol 
respectively in another 50 ml Nalgene centrifuge tube. The plasmid DNA was 
recovered by centrifuging at 27,200 x g for 30 min at 4 °C. The supernatant was 
decanted and the air dried DNA pellet was resuspended with 50 i^l or 0.5 ml TE 
buffer (pH 8), respectively. 
2.2.8 Genomic DNA Extraction From Tissue and Cell Culture 
DNAzoL (1 ml) was added to 50 mg of rat tissue and sample was homogenized 
with a tissue tearor. For cultured cells, DNAzoL (1 ml) was add to cells grown in a 
2 
10 cm cell culture dish. The cell culture products was agitated and pipette with a 
wide bore pipette tip. The homogenate was centrifugated at 10,000 X g at 4 ^C for 
10 min. Then the supernatant was transferred to a fresh tube and 0.5 ml of 100 % 
ethanol was added per 1 ml ofDNAzoL reagent. Samples was mixed by inversion 
and incubated at room temperature for 1 min. The precipitated DNA was removed 
by spooling onto a pipette tip. The pellet was washed with 1 ml of 95 % ethanol 
and centrifugated at 4,000 X g for 2 min and repeated twice. The supernatant was 
discarded and the DNA pellet was let to air dry for 15 min at room temperature. 
The DNA pellet was redissolved in 300 i^l of 8 mM NaOH. The purity and the 
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quantity of extracted genomic DNA was determined by UV absorbance at the ratio 
of260/280 nm. 
2.2.9 RT-PCR Cloning ofMas Oncogene 
The fiill length Mas oncogene was obtained by an RT-PCR menthod (Figure 2.1). 
First strand cDNA synthesis was obtained by using SUPERSCRffT™ II RNase H' 
Reverse Transcriptase (GibcoBRL). Total RNA (5 昭）extracted from AR4-2J cells 
was added to a mixture containing 0.5 i^g Oligo (dT), 4 i^l of 5X First Strand 
Buffer, 2 U^ of 0.1 M DTT, 1 i^l of 10 mM dNTP Mix and 1 i^l (200units) of 
SUPERSCRn>T II in a final volume of20 ^1. The mixture was incubate at 42 'C 
for 1 hr. 
One-tenth of the reverse transcription product was used for PCR analysis. The 
forward and reverse primer sequence were designed base on the reported full length 
Mas sequence (Young et al., 1988). The PCR mixture contained 1 X PCR buffer, 
lmM MgCl2, 0.2 mM dNTP, one-tenth of the reverse transcription product, 1 mM 
each of forward primer (5,-TCA TGG ACC AAT CAA ATA TGA CAT CC-3') 
and reverse primer (5'-TCC TCA GAC CAC AGT CTC AAT GGA T-3') and 5U 
ofTaq DNA polymerase in a final volume of 50 i^l. The standard reaction mixture 
was subjected to PCR with the following conditions: initial denaturation at 94 °C 
for 3 min, then followed by 30 cycles each of denaturation at 94 °C for 30 sec, 
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annealing at 58 °C for 1 min and elongation at 72 °C for 1 min, and a final prolong 
elongation at 72 °C for 5 min. The PCR product was separated on 1% agarose gel 
at constant voltage (120 volt) and the desired fragments were purified by 
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Figure 2.1. Schematic diagram of RT-PCR procedures to obtain a full 
length cDNA of Mas. 
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2.2.10 Construction ofFull Length Mas cDNA into pBluescript® n SK Vector 
The full lengthMos cDNA fragment was cloned into the pBluescript® II SK vector 
by TA cloning. For TA cloning, the plasmid vector was blunt end cut with 10 units 
of restriction endonucleases EcoRV by incubating at 37 °C for 2 hrs and then 
purified by Geneclean II® Kit. Purified plasmid was mixed with 10x PCR buffer, 2 
mM magnesium chloride and 2 mM dTTP, and 5 U of Taq polymerase in a final 
volume of 20 jiL The reaction mixture was incubated at 72°C for 2 hr. The product 
was purified by QIAquick Gel Extraction Kit. The full length Mas cDNA fragment 
and vector were mixed together in 5 to 1 molar ratio to make up a reaction mixture 
containing about O.lp,g DNA. T4 DNA ligase (lU per jig DNA) and ligation buffer 
(lx in final concentration provided by the manufacturer). Finally, the mixture was 
incubated at 16°C overnight. The positive clone was pick to growth in 3 ml LB 
broth and then 1 ml of the overnight culture was added to 750 ml LB broth and 
DNA was purified by Maxiprep (Qiagen). 
2.2.11 Southern Blot Analysis 
2 .2.11.1 Preparation ofDIG-labeled Mas Probe 
The DIG-labeled Mas probe was prepared by Polymerase Chain Reaction (PCR) 
method. The PCR reaction mixture contained IX PCR buffer with lmM MgCl2 , 
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2mM dNTP and Digoxigenin-11-dUTP in a ratio of 5:1, l^iM each of forward and 
reverse primers, 20 ng of Mas cDNA template and 1 unit of Taq polymerase in a 
final volume of 50 ^1. The PCR primers were designed base on the reported 
sequence of fiill length Mas sequence (Young et al., 1988). The forward primer 
sequence is from 452 to 472 (5'-CAG ATG TCA CCG CCC CAA GCA-3') and 
reverse primer is complementary to sequence from 983 to 961 (5'-GTG TTG CCA 
TTG CCC TCC TGA-3'). 
The standard reaction mixture was subjected to a PCR condition as follows: after 
additional denaturation at 94 °C for 3 min, the mixture was subjected to 30 cycles 
of denaturation at 94 °C for 30 sec, annealing at 58 °C for 1 min and elongation at 
72 °C for 1 min, and a final prolong elongation at 72 °C for 5 min. The PCR 
products was separated on 1% agarose gel at a constant voltage (120 volt) and the 
desired fragments were purified by Geneclean II® Kit. 
2.2.11.2 Enzyme Restriction of Genomic DNA 
Genomic DNA extracted from rat pancreas (28.8 ^ig) and AR4-2J cells (20 [xg) 
were digested with 20 units of various restriction enzymes at 37�C for 4 hrs 
respectively. The restriction enzyme include XbaI, BglII, EcoRI, NsiI, XmnI, and 
PstI. Genomic DNA that incubated in the absence of any restriction enzyme was 
used as a control. 
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2.2.11.3 Transferring DNA to Nylon Membrane 
Restricted genomic DNA and 40 ng of DIG-labeled molecular weight markers 
were loaded into a 0.7 % agarose gel and separated with IX TBE running buffer at 
100 volt for 3.5 hrs. The gel was submerged in 250 mM HC1 for 10 min with 
shaking at room temperature and then the gel was rinsed with sterile distilled water. 
The gel was fiarther submerged in a denaturation solution (0.5 M NaOH, 1.5 M 
NaCl) with shaking for 15 min twice and rinsed with sterile distilled water. The gel 
was neutralized by soaking in neutralization solution (0.5 M Tris/HCl pH 7.5, 1.5 
M NaCl) with shaking for 15 min twice and rinsed with sterile distilled water. A 
positive charged Nylon Membrane (Amersham) was cut to the same size of the gel 
and placed directly on top of the gel. The bolt was allowed to transfer overnight 
using 20 X SSC as the transfer buffer by capillary action. While the bolt was still 
damp, DNA was fixed to the blot by UV-crosslinking both sides of the blot. After 
UV-crosslinking, the blot was rinsed briefly in sterile water and was allowed to air-
dry. 
2.2.11.4 Prehybridization and Hybridization 
The blot was placed into a hybridization tube filled with pre-warmed 10 ml DIG 
Easy Hyb and incubated for 2 hrs at 37 °C. After 2 hrs prehybridization, 0.2 i^g of 
boiled DIG labeled Mas probe was added to the prehybridization tube and the bolt 
was allowed to hybridize at 42 °C overnight. 
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2.2.11.5 Post-hybridization Washes and Blocking 
At the end of the hybridization, the hybridization buffer was pour out from the 
tube. The membrane was washed twice for 15 min with 0.5 X SSC/ 0.1% SDS at 
room temperature. Then the membrane was washed twice for 15 min with pre-
warmed 0.1 X SSC/ 0.1 % SDS at 65 "C. 
After washing, the membrane was blocked with a Blocking reagent (1%, W/V in 
Maleic acid buffer) with shaking for 1 hr. Following blocking, an AP-conjugated 
Anti-Digoxigenin-antibody (1:20000) was added to the blocking solution with 
shaking at room temperature for 1 hr. The antibody solution was discarded and the 
membrane was rinsed twice for 20 min at room temperature in a IX Washing 
buffer (O.lM maleic acid, 0.15MNaCl, pH7.5) with shaking. 
2.2.11.6Detection 
The CDP-Star™ was diluted at 1:100 in a Detection solution (100 mM Tris-HCl, 
pH 9.5; 100 mM NaCl). The membrane was incubated with 1 ml CDP-Star™ 
between two sheet of plastic sheet protectors. Then the membrane was pressed 
gently to spread the solution and the excess liquid was squeezed out. Finally, the 
membrane was exposed to an x-ray film (BioMax film, Kodak) for 15 min and 
developed by an autoprocessor (Kodak M35 X-OMAT Processor). 
41 
Chapter 1 
2.2.12 DNA Sequencing 
2.2.12.1 Manual Sequencing 
Manual sequencing was performed by using the T7 Sequenase version 2.0 DNA 
sequencing kit (Amersham). DNA (5 ^ig) of Mas/pBluescript E SK was first 
denatured by dissolving in 100 i^l ofTE buffer with 10 i^l of 2M NaOH and 2 mM 
of EDTA. The mixture was incubated at 37 ^ for 30 min, then 10 i^l of 3 M 
sodium acetate (pH 5.2) was added. DNA was precipitated with 250 i^l of absolute 
ethanol and incubated at -70¾ for 15 min. Afterwards the mixture was 
centrifugated at 15,800 x g for 30 min and the supernatant was discarded. The 
DNA pellet was then washed with 70 % ethanol and centrifugated at 15,800 x g for 
15 min. The supernatant was discarded and DNA pellet was finally dissolved in 7 
Mi of distilled water. T7 Sequenase reaction buffer (2 i^l) and lpM primer (1^1) 
was added to the denatured DNA solution and the reaction mixture was incubated 
at 65 ^C for 2 min. The reaction mixture was allowed to cool down at temperature 
lower than 35 °C then the mixture was chilled on ice. Four eppendorfs were added 
with termination mixture containing either ddATP, ddTTP, ddGTP and ddCTP 
then they were pre-warmed at 37 °C. Labeling mixture and sequenase from the 
sequencing kit were diluted four-fold with water and eight-fold with sequenase 
dilution bufFer, respectively. Sequencing mixture was prepared by adding 1 i^l of 
0.1 M DTT, 2 i^l of diluted labeling mix, 0.5 d^ of [^^S]dATP and 2 i^l of diluted 
42 
Chapter 1 
T7 Sequenase polymerase to the tube containing denatured DNA template and 
sequence primers. They were left at room temperature for 5 min. An aliquot of 
sequencing mixture (3.5 � was transferred to each pre-warmed termination tube 
and incubate at 37 ^C for 5 min. Afterwards, the reaction was stopped by adding 4 
i^l of stop solution. The samples were heated to 75 °C for 2 min and chilled on ice. 
2 fji of each sample was loaded into a well of 5% denaturing polyacrylamide gel 
with 7 M urea and electrophoresed for 4 hr at 1600 V. Subsequently, the gel was 
dried and exposed to an Fuji X-ray film with an intensifying screen at -80 °C 
overnight. 
2.2.12.2 Autosequencing 
The reaction mixture contained 0.5 i^g of double strand DNA template, 8 i^l of 
terminator Ready Reaction Mix from the ABI PRISM dRhodamine Terminator 
Cycle Sequencing Ready Reaction Kit, 4 i^l of0.8 mM of primers and topped up 
with double distilled water to a final volume of 20 jul The standard reaction 
mixture was subjected to PCR under the following conditions: 25 cycles of 
denaturation at 96 X for 10 sec, annealing at 50 ^C for 5 sec and elongation at 60 
°C for 4 min. The PCR product was then added with 2 ml of 3M sodium acetate 
(pH4.6) and 50 ml of 95 % ethanol and incubated at -20 °C for 2 hr. The mixture 
was then centrifugated at 14,000 x g for 30 min and the supernatant was then 
discarded. The DNA pellet was washed with 250 i^l of 75 % ethanol and 
43 
Chapter 1 
centrifugated at 14,000 x g for 5 min. Afterwards, the supernatant was discarded 
and the pellet was air dried. The dried sample was added with 12 i^l of Template 
Suppression Reagent (TSR) and denatured at 95 °C for 2 min in a 0.5 ml sample 
tube. The sample was chilled on ice and autosequencing was performed with an 
ABI PRISM 310 Sequencer. 
2.2.12.3 Sequencing Primers 
Universal primers used in manual sequencing include KS and SK primers, while 
T3 and T7 primer were used in autosequencing. Sequences of primers used in 
sequencing were listed as Table 2.1 
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Table 2.1 Primer lists for Mos>/pBluescript II SK sequencing 
Primer Name Sequence 
Y s 5'-TCG AGG TCG ACG GTA TC-3' 
^ 3'-CTA GGT GAT CAAGAT CGC GC-5' 
~f3 5'-AAT TAA CCC TCA CGAAAG GG-3' 
~T7 3'-CGG GAT ATC ACT CAG CAT AAT G-5' 
Rmas-F2 5'- '^^  CAG ATG TCA CCG CCC CAA GCA • - 3, 
Rmas-F7 5'- ''% ACG TTA TCG GTG ACT TTT CTA TTT 刃^ — 3， 
Rmas-F9 5'-爪 TTT GTG GAG AAC GGG ATC CTC CTC ^^ ^ - 3， 
Rmas-F16 5 ' - � GGT CTT CAC TCC GCT CAT _ - 3 ' 
Rmas-Rll 5 , - � TAA CAT GAG CGG AGT GAA GAC CAA' '" -3， 
Rmas-R12 5,-观 CAT GGT GGT CAC CAA GCA TGA AAG '"^-3' 
Rmas-R13 5'- ' ' ' AGC AAT GGA CAA GTG GGT GAT ATA '^ ^ -3 ' 
2.2.13 Cell Cultures 
The AR4-2J cells was cultured in F-12K medium supplemented with 10% (v/v) 
fetal calf serum. Nffl 3T3 cells were cultured in DMEM supplemented with 10% 
(v/v) calf serum. PC12 cells were cultured in DMEM supplemented with 10% (v/v) 
fetal calfserum and addition of 5% (v/v) horse serum. Penicillin (100 units/ml) and 
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streptomycin (100 ^ig/ml) were added into cultured medium for all cells. Cells were 
growth in 3TC incubator with 5% CO2. 
2.2.14 Protein Assay by Modified Lowery's 
Protein was first extracted from 100 mm cell culture dish with homogenization 
buffer which contained 50 mM Tris HC1; pH 7.4, 1 mM PMSF, 1 mM DDT, 1 mM 
Benzamide and 1 mM Na3VO4. The cell culture dish was rinsed with 10 ml PBS 
\ 
twice and the PBS was aspirated. Homogenization buffer (1 ml) was added to the 
cell culture dish and shaked at room temperature for 10 min. The concentration of 
extracted protein was determined by using a modified Lowery's protein assay 
(Gray et al., 1977). Seven dilutions of bovin serum albumin standard from the 
range of0.8 to 0.05 mg/ml were used as standard. Four dilution of each sample was 
made namely, 5X, lOX, 20X and 40X. Diluted sample (0.1 ml) was mixed with 0.9 
ml water and then 0.1 ml each of 0.15 % sodium deoxycholate and 72 % ice cold 
TCA. The mixture was vortexed and kept at ice- water bath for 30 min. After that 
the mixtures were centrifugated at 15,800 x g at 4 ®C for 5 min, the supernatant 
was discarded. The pellet was redissolved in 1 ml solution A which contains 960 i^l 
of 2 % Na2CO3, 20 ^1 each of 1% CuSO4 and 2 % KNa tartrate and left at room 
temperature for 10 min. Afterwards, 0.1 ml of lN folin reagent was added to the 
mixture and left at room temperature for 30 min. Absorbance was taken at 750 nm 
and the concentration of protein was determined from the standard curve. 
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2.2.15 SDS-PAGE and Western Blot Analysis 
Proteins extracted form cells were analysed by sodium dodecyl sulfate 
� 
polyacrylamide gel electrophoresis (SDS-PAGE) in a Mini-PROTEESF II protein 
electrophoretic apparatus (Bio-Rad) with 10 - 12.5 % acrylamide separating gel 
and 5 % acrylamide stacking gel. The protein samples were resuspended in 2 X 
SDS-PAGE sample buffer in 1 to 1 volume ratio and the samples were heated at 
100�C for 5 min. The protein gel were run in 1 X SDS-PAGE running buffer 
which contains 25 mM Tris, 192 mM glycine, 0.1 % SDS at 120 V for 2.5 hr until 
the bromophenol blue dye passed the bottom of separating gel. After that the 
protein in the polyacrylamide gels were transferred to a nitrocellulose membrane 
by using a Semi-dry Blotter (Owl) at 15 V for 1 hr in the 1 X transfer buffer 
containing 25 mM Tris, 192 mM glycine, 0.1 % SDS and 20 % methanol. The 
membrane was blocked with a immuno-blotting buffer II containing 5 % dry milk, 
0.02 % NaN3, 19.8 mM Tris-HCl and 0.15 M NaCl at room temperature for 1 hr. 
Afterwards, the membrane was incubated with anti-rabbit Ma^-antiserum in 
1:1,000 dilution at room temperature overnight. Then the membrane was washed 
with 10 ml immuno-blotting buffer 11, followed by incubating with alkaline 
phosphatase conjugated goat anti-rabbit IgG (H+L) antibody in 1:1,000 dilution in 
the presence of 2 mM levamisole at room temperature for 2 hr. After excessive 
washing with Buffer 3 which contains 0.1 M Tris.Cl (pH 9.5), 0.05 M MgC^ and 
0.1 M NaCl and 2 mM levamisole. The immunoreactive band was detected by 
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adding 0.187 mg X-phosphate/5-Bromo-4-chloro-3-indolyl-phosphate (BCEP) and 
0.5 mg 4-nitro blue tetrazolium chloride (NBT) in Buffer 3 solution for 0.5 hr 




Previous study from our laboratory has shown that pancretoma AR4-2J cells 
expressed a functional ATiA receptor. In order to evaluate whether Mas oncogene 
is co-expressed with ATiA receptor in AR4-2J cells, Western blot was performed 
with an mXi-Mas antibody. Two immunoreactive bands with relative molecular 
mass of 48 kDa and 72 kDa were observed in the membrane fraction of AR4-2J 
cells (Figure 2.2). Therefore, to further confirm the expression of Mas oncogene, 
RT-PCR was performed. Full length Mas oncogene was obtained by using forward 
and reverse primers of which sequences were designed based on the reported full 
length Mas sequence (Young et al., 1988). A cDNA fragment about 1 kb was 
obtained (Figure 2.3). The 1 kb cDNA was subcloned into pBluescript® II SK 
vector by TA cloning. Sequences of the 1 kb clone was obtained by manual and 
auto sequencing. Full length sequences was constructed from various overlapping 
fragments sequencing at both side (Figure 2.4) and an open reading frame of 972 
bp was obtained (Figure 2.5). In order to compare the obtained sequence with the 
\ 
published X2XMas sequence (Young et al.，1988)，alignment ofthe DNA sequences 
was performed (Figure 2.6). Results showed that there were two changes in the 
nucleotide, one within the coding region from A to G (426 bp) while the other is in 
the noncoding region from T to C (960 bp). Though there was change of one 
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Figure 2.2 Western blot analysis of Mas proton-oncogene expression in 
AR4-2J cell. Protein (30 i^g) harvested from AR4-2J cells. Pre-stained protein 
size markers are shown on lane M. Membranes were probed with a polyclonal 
anti-May Ab (1:1000 dilution) in the absence (panel A) and presence(panel B) 
of a Mas peptide (2 ^ig/ml) which was used to raise the anti-Mos antibody in 
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Figure 2.3 A lkb cDNA fragment was obtained by RT-PCR The 
lkb ladder markers is shown in lane M. 
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Figure 2.4 The arrow represent the overlapping fragments which were 
sequenced with primers listed above the arrow bars. 
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* * * 
1 AGAACTAGTG GATCCCCGGG CTGCAGGAAT TCGATCATGG ACCAATCAAA 
51 TATGACATCC TTTGCTGAGG AGAAAGCCAT GAATACCTCC AGCAGAAATG 
1 0 1 CCTCCCTGGG GACTTCACAC CCACCCATTC CCATAGTGCA CTGGGTCATC 
1 5 1 ATGAGCATCT CTCCTCTCGG CTTTGTGGAG AACGGGATCC TCCTCTGGTT 
2 0 1 CCTTTGCTTC CGGATGAGGA GAAATCCCTT CACGGTCTAT ATCACCCACT 
2 5 1 TGTCCATTGC TGACATCTCC CTCCTGTTCT G T A T T T T T A T TCTGTCCATC 
3 0 1 GACTATGCTT TAGACTATGA ACTCTCTTCT GGCCATTACT ACACAATCGT 
3 5 1 GACGTTATCG GTGACTTTTC TATTTGGCTA CAACACAGGC CTCTATCTGC 
4 0 1 TGACAGCCAT CAGTGTGGAG AGATGCCTTT CGGTCCTCTA CCCCATCTGG 
4 5 1 TACAGATGTC ACCGCCCCAA GCACCAGTCG GCATTCGTCT GTGCCCTCCT 
5 0 1 GTGGGCACTT TCATGCTTGG TGACCACCAT GGAGTACGTC ATGTGTATTG 
5 5 1 ACAGCGGAGA AGAGAGTCAC TCTCAGAGTG ACTGTCGGGC GGTCATCATC 
6 0 1 TTCATAGCCA TCCTCAGCTT CTTGGTCTTC ACTCCGCTCA TGTTAGTGTC 
6 5 1 CAGCACCATC TTGGTGGTGA AGATACGGAA GAACACATGG GCCTCCCATT 
7 0 1 CTTCGAAGCT GTACATCGTC ATCATGGTCA CCATTATCAT ATTCCTCATC 
7 5 1 TTTGCCATGC CCATGCGGGT CCTCTACCTG TTGTATTACG AGTACTGGTC 
8 0 1 AACCTTTGGG AACCTGCATA ACATCTCCTT GCTTTTCTCC ACCATCAATA 
8 5 1 GCAGCGCCAA CCCTTTCATC T A C T T T T T T G TGGGCAGCAG TAAGAAGAAG 
9 0 1 CGCTTCAGGG AGTCCTTAAA AGTGGTCCTC ACCAGAGCTT TCAAAGACGA 
9 5 1 GATGCAACCT AGGCGCCAGG A G G G C A A T ^ CAACACTGTA TCCATTGAGA 
1 0 0 1 CTGTGGTCTG AGGAATCAAG CTTATCGATA CCGTCG 
Figure 2.5 Sequencing results of the lkb PCR fragment. The start codon is 




Query: 29 tcatggaccaatcaaatatgacatcctttgctgaggagaaagccatgaatacctccagca 88 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 35 tcatggaccaatcaaatatgacatcctttgctgaggagaaagccatgaatacctccagca 94 
Query: 89 gaaatgcctccctggggacttcacacccacccattcccatagtgcactgggtcatcatga 148 
I I I 1 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I Sbjct: 95 gaaatgcctccctggggacttcacacccacccattcccatagtgcactgggtcatcatga 154 
Query: 149 gcatctctcctctcggctttgtggagaacgggatcctcctctggttcctttgcttccgga 208 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 155 gcatctctcctctcggctttgtggagaacgggatcctcctctggttcctttgcttccgga 214 
Query: 209 tgaggagaaatcccttcacggtctatatcacccacttgtccattgctgacatctccctcc 268 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 215 tgaggagaaatcccttcacggtctatatcacccacttgtccattgctgacatctccctcc 274 
Query: 269 tgttctgtatttttattctgtccatcgactatgctttagactatgaactctcttctggcc 328 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 275 tgttctgtatttttattctgtccatcgactatgctttagactatgaactctcttctggcc 334 
Query: 329 attactacacaatcgtgacgttatcggtgacttttctatttggctacaacacaggcctct 388 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 335 attactacacaatcgtgacgttatcggtgacttttctatttggctacaacacaggcctct 394 
Query: 389 atctgctgacagccatcagtgtggagagatgcctttcagtcctctaccccatctggtaca 448 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 395 atctgctgacagccatcagtgtggagagatgcctttcggtcctctaccccatctggtaca 454 
Query: 449 gatgtcaccgccccaagcaccagtcggcattcgtctgtgccctcctgtgggcactttcat 508 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 455 gatgtcaccgccccaagcaccagtcggcattcgtctgtgccctcctgtgggcactttcat 514 
Query: 509 gcttggtgaccaccatggagtacgtcatgtgtattgacagcggagaagagagtcactctc 568 
. I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 515 gcttggtgaccaccatggagtacgtcatgtgtattgacagcggagaagagagtcactctc 574 
Query: 569 agagtgactgtcgggcggtcatcatcttcatagccatcctcagcttcttggtcttcactc 628 
, I I I I i I I I i I I I I I i I I I I I I I I I I I I I i I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 575 agagtgactgtcgggcggtcatcatcttcatagccatcctcagcttcttggtcttcactc 634 
Query: 62 9 cgctcatgttagtgtccagcaccatcttggtggtgaagatacggaagaacacatgggcct 688 
. I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I Sbjct: 635 cgctcatgttagtgtccagcaccatcttggtggtgaagatacggaagaacacatgggcct 694 
Query: 689 cccattcttcgaagctgtacatcgtcatcatggtcaccattatcatattcctcatctttg 748 
I I I I丨丨I丨丨丨丨I丨丨I I丨I丨丨I I丨丨I丨I丨I丨丨丨I I 
Sbjct: 695 cccattcttcgaagctgtacatcgtcatcatggtcaccattatcatattcctcatctttg 754 
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Query: 749 ccatgcccatgcgggtcctctacctgttgtattacgagtactggtcaacctttgggaacc 808 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 755 ccatgcccatgcgggtcctctacctgttgtattacgagtactggtcaacctttgggaacc 814 
Query: 809 tgcataacatctccttgcttttctccaccatcaatagcagcgccaaccctttcatctact 868 
I I I I 1 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 815 tgcataacatctccttgcttttctccaccatcaatagcagcgccaaccctttcatctact 874 
Query: 869 tttttgtgggcagcagtaagaagaagcgcttcagggagtccttaaaagtggtcctgacca 928 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 875 tttttgtgggcagcagtaagaagaagcgcttcagggagtccttaaaagtggtcctgacca 934 
Query: 929 gagctttcaaagacgagatgcaacctaggcgtcaggagggcaatggcaacactgtatcca 988 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 935 gagctttcaaagacgagatgcaacctaggcgccaggagggcaatggcaacactgtatcca 994 
Query: 989 ttgagactgtggtctgagga 1008 
I I I ！ I I I I I I I I I I I I I i I I 
Sbjct: 995 ttgagactgtggtctgagga 1014 
Figure 2.6 Alignment of the full-length Mas clone with the published Mas sequeces 
(Accession no. J03823) was performed in Nffl BLAST Search 2.0. There are two 
nucleotides changes, one in coding sequence at 426 bp (from A to G) and other one in 
non-coding region at 960 bp (from T to C). The start codon is indicated by * and stop 
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Figure 2.7 Amino acid sequence alignment of the 1 kb full-lengthMa^ clone with 
the publishedMa^ sequence (Accession no. J03823) was performed by M H BLAST 
Search 2.0 showing that there is no change in the encoded amino acid sequence. 
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Rearrangement of the 5' upstream non-coding region of Mas oncogene has been 
detected in M H 3T3 cells transfected with genomic DNA from human epidermoid 
carcinoma (Young et al., 1986) and human ovarian tumor (Van't Veer et al., 1988). 
Furthermore, activation of the Mas oncogene was observed during transfection of 
human acute myelocytic leukemia, showing that rearranged and amplified Mas 
sequence were detected in secondary and tertiary tumors by using Southern blot 
when compared to the normal Mas in human placenta. (Janssen et al., 1988). In 
order to analyse whether of the 5’ upstream non-coding region QiMas oncogene is 
rearranged in AR4-2J cells, a Southern blot was performed. Firstly, a DIG-labeled 
550 h^Mas probe that corresponds to the 3, end of the Mas oncogene from 452 to 
983 was prepared by PCR with dNTP and DIG labeling mix in the ratio of 5:1 
(Figure 2.8). Secondly, genomic DNA extracted form rat pancreas and AR4-2J 
cells was digested with 6 restriction endonucleases, separated on an agarose gel and 
blotted to a Nylon membrane. The blot was prehybridized with the DIG Easy Hyb 
buffer and then hybridized with the DIG-labeled Mas probe. However, no obvious 
rearrangement in the 5，non-coding region was obtained within the fragment size 
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Figure 2.8 The DIG-labeled Mas probe was obtained by PCR method. 
The original Mas probe size was 550 bp，with DIG labeling, the size ofthe 
Mas probe was changed from 550 bp to 700 bp. The 100 bp ladder DNA 
markers is shown in lane M. 
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Figure 2.9 Genomic Southem blot analysis of 5'rearrangement ofMas oncogene 
in AR4-2J cells. Genomic DNA from rat pancreas (28.8 i^g, lanes 1，3，5, 7, 9，11 and 
13) and AR4-2J cells (20 昭，lanes 2，4，6，8，10 and 12) were digested with XbaI 
(lanes 3&4), BgUI (lanes 5&6)，EcoRI (lanes 7&8), NsiI (lanes 9&10), XmnI (lanes 
11&12)，and PstI (lanes 13&14). Uncut control of pancreas and AR4-2J cells were 
shown in lanesl&2, respectively. A DIG labeled DNA fragment corresponding to the 
3，end region ofMas oncogene was used as a probe. DIG-labeled DNA size markers 




Previous studies have suggested that Mas oncogene is activated by rearrangement 
in the 5’ upstream non-coding region (Young et al., 1986, Van't Veer et al., 1988 
and Janssen et al., 1988). The full-length Mas sequence from pancretoma AR4-2J 
cells shows there is no change in the coding protein sequence though there is a 
change of nucleotide from A to G within the coding region (426 bp). The protein 
sequence agreed with the published sequences (Young et al., 1988). However, 
results from Southern blot showed that there was no such rearrangement in the 5， 
non-coding region in AR4-2J cells when probed with the DIG-labeled Mas probe. 
Therefore, the Southern blot result suggested that rearrangement in the 5’ upstream 
non-coding region is not necessary for the activation o^Mas oncogene. 
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Chapter 3 Analysis ofMas Transfected Cell Lines 
3.1 Introduction 
\nMas stably transfected neuronal cell line 401L-C3, stimulation of angiotensin 
receptor leads to accumulation of inositol phosphates and elevation of 
intracellular calcium ion concentration and pH, the potencies of ANG III and 
ANGII in eliciting calcium ion are greater than ANG I in 401L-C3 (Jackson et 
al., 1989). Moreover, angiotensin stimulated 401L-C3 displays a change in the 
levels of inositol phosphates and phospholipids (Poyner et al., 1990). 
Cytoplasmic calcium measurements of transiently transfected Mas in Cos-7 
cells shows an increase in ANG II response. The increase of cytoplasmic 
calcium is dose-dependent with ANG II and the potency of ANG II is more 
active than ANG III. Moreover, the response is completely inhibited by ANG II 
antagonists. However, such response is not detectable in micro injection ofMas 
RNA transcripts into Xenopus oocytes and other transient transfected Mas cell 
line such as Cos-7, FRTL-5, CHO and PC12 cells (Ambroz et al., 1991). 
Though Mw"-transfection endows angiotensin response in some cells, Mas and 
cloned angiotensin receptors share limited similarity (less than 20%). In order 
to evaluate the possibility that expression ofMas gene leads to the expression of 
endogenous ANG II receptor, both transient and stably Mas transfected cells 




3.2 Materials and Methods 
3.2.1 Materials 
> 
Materials for cell culture, Western blot analysis and antibodies were described 
in section 2.1.1. Protein Assay ESL kit was obtained from Boehringer 
Mannheim. Fluorescent SEAP assay kit from Clontech. 
3.2.2 Cell Culture and Transfection 
3.2.2.1 Cell Culture 
The AR4-2J cells were grown in F-12K medium supplemented with 10% (v/v) 
fetal calf serum. AlO cells, AR4-IP cells, Cos-7 cells and Swiss3T3 cells were 
cultured in DMEM supplemented with 10% (v/v) fetal calf serum (FCS). 
MH3T3 cells were grown in 10% (v/v) calf serum. PC12 cells were cultured in 
DMEM supplemented with 10% (v/v) fetal calf serum and addition of 5% (v/v) 
horse serum (HS). Penicillin (100 units/ml) and streptomycin (100 ^g/ml) were 
added into culture medium for all cells. Cells were grown at 37�C with 5% CO2. 
3.2.2.2 Transfection Optimization 
In a six-well cell culture plate, cells were initially seeded at a density o f 2 x 10^  
cells/per well with the growth medium supplemented with 10% FCS. The cells 
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were incubated at 3TC in a CO2 incubator and cells were let to reach confluent. 
In the next day solution A was prepared by adding 2 i^g DNA (pSEAP2-Control 
vector) into medium. Solution B was prepared by adding diluted 0-20 |Lil of 
Lipofectamine Reagent into 500 jjl serum-free medium and allowed to 
incubated at room temperature for 30 min. Afler that solution A and B was 
combined by mixing gently and then allowed to incubate at room temperature 
for 10 min. The seeded cells were washed with PBS and loaded with the 
reaction mixture of solution A and B. Afterwards, cells were incubated at 3TC 
in a CO2 incubator for 6 hr and replaced with normal growth medium 
containing serum and incubate cells at 2TC in a CO2 incubator for 24 hr. 
3.2.2.3 Fluorescent SEAP Assay 
Sufficient amount of assay buffer was allowed to equilibrate to room 
temperature. The IX Dilution buffer was prepared by adding 4 volume of 
distilled water with 1 volume of 5X Dilution buffer, and the mixture was 
allowed to reach room temperature. Each sample medium (25 ^1) was placed 
into a separate well of a 96-well plate. After that 25 i^l of IX Dilution buffer 
was mixed with 25 i^l sample medium. Diluted samples were incubated at 65^C 
for 30 min with the lid of 96-well plate put on. Afterwards, samples were cool 
to room temperature by placed on ice for 2 to 3 min and then equilibrated to 
room temperature. Then 97 |il of assay buffer was added to each sample and 
incubated at room temperature for 5 min. Meanwhile, 1 mM 4-
methylumbellifery phosphate (MUP) was prepared by diluting 1 volume o fa 10 
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mM MUP stock solution with 9 volume of IX Dilution buffer. And then 3 i^l of 
the 1 mM MUP working dilution was added to each sample and incubated in 
the dark at room temperature for 60 min. Finally, the fluorescence detection was 
performed with the Cytofluor II Fluorescence Multiwell Plate Reader, with the 
excitation and emission peaks ofMUP at 360 nm and 449 nm, respectively. 
3.2.2.4 Transient Transfection 
Cells were seeded in a 6-well plates at an initial density of 4 x 10^  cells per well 
24 hr prior transfection. Lipofectamine (48 i^l) and pOPRSWMa5^ (12 ^ig) were 
added to serum free medium (3 ml) separately and incubated at room 
temperature for 30 min. Then the lipofectamine and DNAs were mixed together 
and incubated at room temperature for 15 min. Cells were washed with PBS, 
reaction mixture (1 mL) was added into each well and than the plates were 
incubated in a 37�C incubator with 5% CO2 for 5 hrs. Afterwards, the cells were 
washed and grown in normal growth medium for one day. 
3.2.2.5 Stable Cell Lines Construction 
The procedures of preparation of lipofectamine and pOPRSVI/A/as prior to 
transfection as described in section 3.2.2.3. In next day, cells were growth in 
medium supplement with 400 i^gAiil G418 and cells were growth for 2 weeks. 
After that the stable cell lines were grown in medium without G418. 
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3.2.3 Protein Assay ESL 
Reagent A (alkaline copper tartrate solution) and Reagent B (ascorbic acid, 
bathocuproine disulfonic acid solution) was allowed to warm to room 
temperature by placing in 37°C water bath. A series of standards range from 50 
M-g/ml to 750 ^ig/ml was prepared by diluting a BSA protein stock (2 mg/ml). 
Reagent A (100 i^l) was added to 1.5 ml eppendorf, after that 50 [i\ of standard 
or sample was added to the eppendorf and mix by inverting the tube. The 
mixture was allowed to incubate at room temperature for 15 min. Then 1 ml of 
Reagent B was added to the reaction mixture and mixed gently. After 
incubation at room temperature for 30 sec, the whole mixture was transferred to 
the 1 ml cuvette and absorbance was measured at 485 nm against water. Finally, 
a calibration curve was constructed by plotting absorbance of the standards 
against their concentration. While the protein concentration of unknown 
samples was calculated from the calibration curve. 
3.2.4 SDS-PAGE and Western Blot Analysis 
The method ofWestern blot was described in section 2.2.10 in Chapter 2. 
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3.2.5 Preparation of an ATiA Receptor Internal Standard for Quantitative 
RT-PCR Analysis 
3.2.5.1 Preparation ofan ATiA Receptor cDNA by RT-PCR 
First strand cDNA synthesis was obtained by using SUPERSCRDPT™ II RNase 
H" Reverse Transcriptase (GibcoBRL). RNA (5 ^ig) extracted from rat liver 
tissue was incubated with 1.5 U ofDNase I in a final volume of 11 i^l at 37 ®C 
for 40 min and heat inactivated at 75 °C for 15 min. Afterwards the total 
mixture was added with 1 i^l of 0.5 ^g Oligo (dT), 4p,l of 5X First Strand 
Buffer, 2 i^l of 0.1 M DTT, 1 ^1 of 10 mM of dNTP and 1 i^l (200units) of 
SUPERSCRIPT II. The mixture was incubate at 42 "C for 1 hr. 
One-tenth of the reverse transcription product was used for PCR analysis. 
Forward primer (5'-TGG GCA TTG TGC TTT TCT TC-3') and reverse primer 
(5'-GGG TGA ATG GTC CTT TGG TC-3') were chosen corresponding to 
nucleotide 992 to 1002 and 1409 to 1428 of cloned ATiA receptor (Iwai et al., 
1991). The PCR mixture contained 1 X PCR buffer, 1.5 mM 0fMgCl2, 0.2 mM 
of dNTP, one-tenth of the reverse transcription product, 0.5 mM of each 
forward and reverse primers and 5U ofTaq DNA polymerase in a final volume 
of 25 nl. The standard reaction mixture was subjected to PCR under the 
following conditions: an initial denaturation at 94 °C for 3 min, then 30 cycles 
ofdenaturation at 94 °C for 30 sec, annealing at 58 °C for 30 sec and elongation 
at 72 °C for 45 sec, and a final prolong elongation at 72 °C for 5 min. The PCR 
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product was separated on 1% agarose gel at constant voltage (120 volt) and the 
desired fragments were purified by QIAquick Gel Extraction Kit. 
3.2.5.2 Cloning ofATiA Receptor cDNA into pBluescript® II SK Vector 
The ATiA receptor cDNA fragment (450 bp) was cloned into pBluescript® 11 
SK vector by TA cloning. For TA cloning, the plasmid vector was blunt end cut 
with 10 units of restriction endonucleases EcoRV by incubating at 37 °C for 2 
hrs and then purified by QIAquick Gel Extraction Kit. Purified plasmid was 
mixed with 10x PCR bufFer, 2mM magnesium chloride 2mM dTTP and 5 U of 
Taq polymerase in a final volume of 20 i^l. The reaction mixture was incubated 
at lTC for 2 hr. The product was purified by QIAquick Gel Extraction Kit. The 
ATiA receptor cDNA fragment and vector were mixed together in 5 to 1 molar 
ratio to make up a reaction mixture containing about O.l^ig DNA. T4 DNA 
ligase (lU per i^g DNA) and ligation buffer (lx in final concentration) provided 
by the manufacturer were added to the reaction mixture. Finally, the mixture 
was incubated at 16¾ overnight. The positive clone was screen by digestion 
with Hind III and EcoRI endonuclease that yield a 500 base pair DNA 
fragment. The positive clone was picked and grown in 3 ml LB broth. Then 1 
ml overnight culture (1 ml) was added to 750 ml LB broth. Plasmid DNA was 
purified by Maxiprep (Qiagen). 
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3.2.5.3 Autosequence ofpBluescript® II SKv'ATiA R 
The method of autosequencing was described in section 2.12.2. Universal 
primers used in auto sequencing include M13 reverse, M13 (-20) and M13 (-
21). Primer sequences of primers used in sequencing are listed in Table 4.1. The 
nucleotide number listed on the primer sequence corresponding to the same 
nucleotide number listed on the original sequence of ATiA with an accession 
number M74054 in the GenBank. 
Table 4.1 Primer lists for ATiA fragment sequencing 
Primer Name Sequence 
M13(20) 
5'-GTA AAA CGA CGG CCA T-3' 
M13(-20) 5'-TGT AAA ACG ACG GCC AGT-3, 
M13 reverse 
5'-CAG GAA ACA GCT ATG AC-3' 
ATiAR-Fl : 
5，- 987TGGCGATTGTGC TTT TCT TC 匪 - 3 ' 
ATiAR-Rl ~ 
5 ' - 剛 G G G T G A A T G G T C C T T T G G 几 濯 — 3 ， 
3.2.5.4 Preparation of 100 bp Deleted ATiA Receptor cDNA by RT-PCR 
The strategy for preparation of 100 bp deleted ATiA receptor fragment was 
shown in (Figure 3.1). In the first round PCR, one-tenth of the reverse 
transcription product was used for PCR analysis. Forward primer F2 (5'-TGT 
GCT TTT CT TCC ATG CC-3') and reverse primer R1 (5'-GGG TGA ATG 
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GTC CTT TGG TC-3') were chosen. In the forward primer, the first 8 base in 
the 5，end and the other 12 base in the 3，end corresponding to nucleotide 994 
tol001 and nucleotide 1103 to 1114. The reverse primers were complementary 
to nucleotide 1409 tol428 ofcloned ATiA receptor (Iwai et al., 1991). The PCR 
mixture contained 1 X PCR buffer, 1.5 mM MgCl2, 0.2 mM dNTP, one-tenth of 
the reverse transcription product, 0.5 mM of each forward and reverse primers 
and 5U of Taq DNA polymerase in a final volume of 25 i^l. The standard 
reaction mixture was subjected to PCR under the following conditions: an 
initial denaturation at 94 °C for 3 min, 30 cycles of denaturation at 94 °C for 30 
sec, annealing at 58 °C for 30 sec and elongation at 72 °C for 45 sec, and a final 
prolong elongation at 72 °C for 5 min. In the second round PCR, one out ofthe 
fifty of the PCR product from the first round PCR was used for the other PCR 
reaction with the forward primer F1 (5'-TGG CGA TTG TGC TTT TCT TC-
3，）which is corresponding to the nucleotides 987 to 1006 of cloned ATiA 
receptor (Iwai et al., 1991)and reverse primer R1. The PCR condition was the 
same as mentioned in the first round PCR. The PCR product was separated on 
1% agarose gel at constant voltage (120 volt) and the desired fragments were 
purified by QIAquick Gel Extraction Kit. 
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First round PCR by Forward Primer2 and Reverse Primer 1 
I ~ 100 b p ~ , R ^ s e Primer 1 
cDNA^ | , , , , , ^ ^ •“ 
l==n d " ^ _ 
Forward Primer 1 Forward Primer 2 
V 
Synthesis of 100 bp deleted AT^^ receptor fragment 
cn ~ j 
Second round PCR by Forward Primerl and Reverse Primerl 
^ 
C = f l > 
V 
Synthesis of 100 bp deleted AT^^ receptor fragment 
I = • 




3.2.5.5 Cloning of 100 bp Deleted ATiA R cDNA into pCAP^ Vector 
(ATiARy^pCApS) 
s 
The deletion variant ofATiA cDNA fragment was cloned into the pCAP vector 
by blunt end cloning. For blunt end cloning, the plasmid vector (10 ng) was 
digested with 1 unit of restriction endonucleases Mlu NI by incubating at 37 °C 
for 5 min and then the restriction enzyme was inactivated at 65 °C for 15 min. 
The deletion variant of ATiA receptor cDNA fragment and vector were mixed 
together in 100 to 1 molar ratio to make up a reaction mixture containing about 
O.l^ig DNA. T4 DNA ligase (5U)，10 i^l of ligation buffer (lx in final 
concentration) and 2 i^l T4 DNA dilution buffer provided by the manufacturer 
were added to the reaction mixture. Finally, the mixture was incubated at 16¾ 
overnight. The positive clone was picked and growth in 3 ml LB broth and 1ml 
of the overnight culture was added to 750 ml LB broth. Plasmid DNA was 
purified by Maxiprep (Qiagen). 
3.2.6 Construction ofFull Length Mas cDNA into pOPRSVLMCS 
Operator Vector 
The HindIII/EcoRI full lengthMos cDNA was subcloned from pBluescript® II 
SYJMas (mentioned in section 2.2.13), and the 1Kb fragment was end filled 
with DNA polymerase I Large (Klenow) fragment. Following gel purified by 
Geneclean II® Kit, the Mas cDNA fragment was cloned into the 
pOPRSWMCS Operator vector (Stratagene) by blunt end cloning. For blunt 
end cloning, the plasmid vector was blunt end cut with 10 units of restriction 
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endonucleases EcoRV at 37 °C for 2 hrs and then purified by Geneclean II® 
Kit. The full length Mas cDNA fragment and vector were mixed together in 5 to 
1 molar ratio to make up a reaction mixture containing about 0.1 ^ ig DNA, T4 
DNA ligase (lU per i^g DNA) in IX ligation buffer. Finally, the mixture was 
incubated at 16¾ overnight. The positive clone was pick to growth in 3 ml LB 
broth and 1 ml of the overnight culture was added into 750 ml LB broth. 
Plasmid DNA was purified by Maxiprep (Qiagen). 
3.2.7 Preparation of an Mas Internal Standard for Quantitative RT-PCR 
Analysis 
3.2.7.1 Preparation of 100 bp DeletedMos cDNA by RT-PCR 
The strategy of obtaining 100 bp deleted Mas gene was the same as that of 
obtaining 100 bp deleted ATiA R (Figure 3.1). One-tenth of the reverse 
transcription product was used for PCR analysis. The reverse primer RI 
sequence were designed base on the reported sequence of full length Mas 
(Young et al., 1955) as described in section 2.2.11.1in Chapter 2. In the first 
round PCR, forward primer DF2 (5'-CCC AAG CAG ACA GCG GAG-3') 
composed of two domains, the first 8 nucleotide from the 5'end was 
corresponding to nucleotide 461 to 468, while the next 10 bp near the 3, end 
was corresponding to nucleotide 545 to 554 from the cloned raiMas (Accession 
no. J03823). The PCR mixture contained 1 X PCR buffer, lmM MgCl2, 2 mM 
dNTP, one-tenth of the reverse transcription product, 1 mM each offorward and 
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reverse primer and 5U ofTaq DNA polymerase in a final volume of 50 pil. The 
standard reaction mixture was subjected to PCR under the following conditions: 
an initial denaturation at 94 °C for 3 min, 30 cycles of denaturation at 94 °C for 
30 sec, annealing at 58 °C for 1 min and elongation at 72 °C for 45 see, and a 
final prolong elongation at 72 ^C for 5 min. In the second round PCR, one out 
of the fifty of the PCR product from the first round PCR was used for the other 
PCR reaction with the forward, reverse primers and PCR conditions mentioned 
in section 2.2.11.1. The PCR product was separated on 1% agarose gel at 
constant voltage (120 volt) and the desired fragments were purified by 
QIAquick Gel Extraction Kit. 
3.2.7.2 Cloning of 100 bp DeletedMz^ cDNA into pCAP^ Vector (Mos/pCApS) 
The 100 bp deleted Mas cDNA fragment was cloned into the pCAP^ vector by 
blunt end cloning. For blunt end cloning, the plasmid vector (10 ng) was 
digested with 1 unit ofrestriction endonucleases Mlu NI by incubating at 37 °C 
for 5 min and then the restriction enzyme was inactivated at 65 ^C for 15 min. 
The deletion variant ofMas cDNA fragment and vector were mixed together in 
100 to 1 molar ratio to make up a reaction mixture containing about 0.1|iig 
DNA, 1 i^l of T4 DNA ligase (5U per ^d), 10 i^l ligation buffer (lx in final 
concentration) and 2 i^l of T4 DNA dilution buffer provided by the 
manufacturer in a final volume of 20 i^l. Finally, the mixture was incubated at 
16 °C overnight. The positive clone was pick to grow in 3 ml LB broth and 1 ml 
of the ovemight culture was added into 750 ml LB broth. Plasmid DNA was 
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purified by Maxiprep (Qiagen). 
3.2.8 Quantitative RT-PCR Analysis ofATiA R Expression 
ThelOO bp deleted clone of cDNA from ATiA R/ pCAP^ was used as an internal 
s 
control. To construct a standard curve, the ATiA R/pCAP was serially diluted 
starting form 10 i^g with 2.5 folds dilution each time until it reached 4 pg. Total 
RNA from samples was reverse transcripted into cDNA as described in section 
2.2.12. For quantitative RT-PCR , the PCR mixture contained 1 pl of 16 fold 
diluted cDNA, 1 X PCR buffer, 1.5 mM MgCl2, 0.2 mM dNTP, 1 i^l of 
appropriate diluted internal standard, 1 mM each of forward primer (5'-TGG 
GCA TTG TGC TTT TCT TC-3'), reverse primer (5'-GGG TGA ATG GTC 
CTT TGG TC-3'), and 5U ofTaq DNA polymerase in a final volume of 25 i^l. 
The reaction mixture was subjected to PCR under the following conditions: an 
initial denaturation at 94 ®C for 3 min, 30 cycles of denaturation at 9 4 � C for 30 
sec, annealing at 58 ®C for 30 sec and elongation at 7 2 � C for 30 sec, and a final 
prolong elongation at 72 °C for 3 min. The PCR product was separated on 1% 
agarose gel at constant voltage (120 volt). 
3.2.9 Quantitative RT-PCR Analysis for the Expression ofMas 
ThelOO bp deleted Mas cDNA from Mas! pCAP^ was used as an internal 
control. To construct a standard curve, the Ma^/pCAP^ was serially diluted 
starting from 100 pg with 5 folds dilution each time until it reached 6.4 x 10"^  
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pg. Total RNA from samples was reverse transcribed into cDNA as described in 
section 2.2.12. For quantitative RT-PCR , the PCR mixture contained 1 i^l of 8 
fold diluted cDNA, 1 X PCR buffer, 1.5 mM MgCl2, 0.2 mM dNTP, 1 i^l of 
appropriate diluted internal standard, 1 mM each of forward primer (5'-TCA 
TGG ACC AAT CAA ATA TGA CAT CC-3'), reverse primer (5'-TCC TCA 
GAC CAC AGT CTC AAT GGA T-3'), and 5U of Taq DNA polymerase in a 
final volume of 25 i^l. The PCR condition was the same as described in section 





The possibly that expression of Mas oncogene enhances angiotensin receptor 
expression was tested by examining the levels of ATiA mRNA after Mas 
transfection. First of all, cell lines which do not express the Mas oncogene 
endogenously was screened by Western blot. Various parental cell lines 
including PC12, Cos-7, ECV304 cells were screened initially. The Western blot 
of those cell lines was probed with a polyclonal anti-Mos Ab in the absence 
(panel A) or presence (panel B) of the Mas peptide (Figure 3.2). Results of 
figure 3.2 show that two immnoreactive bands (72 and 48 kDa) were detected. 
Similar results were obtained from protein blot of AR4-2J, AR4-ff, AlO & 
PC12 cells (Figure 3.3 & 3.4). Moreover, an immunoreactive band with relative 
molecular mass larger than 100 kDa was also observed in some cell lines such 
as AlO and AR4-IP cells. However, the appearance of this band is inconsistent 
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Figure 3.2 Western blot analysis of Mas proton-oncogene expression in 
various cells lines. Protein (30 ^ig) harvested from Cos-7 cells, PC12 cells and 
ECV304 cells. Pre-stained protein markers are shown on lane M. Membranes were 
probed with a polyclonal anti-Mw Ab (1:1000 dilution) in the absence (panel A) 
and presence (panel B) of the Mas peptide (2 |ig/ml) which was used to raise the 
anti-Mas antibody in rabbit. The close triangle represent the desired 
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Figure 3.3 Westem blot analysis of Mas proton-oncogene expression in 
various cells lines. Protein (30 ^ig) harvested from AR4-2J cells, AR4-ff cells, 
AlO cells and PC12 cells. Pre-stained protein markers are shown on lane M. 
Membranes were probed with a polyclonal anti-Mas Ab (1:1000 dilution) in the 
absence (panel A) and presence (panel B) of the Mas peptide (2 ^ig/ml) which 
was used to raise the anti-Ma^ antibody in rabbit. The close triangle represent the 
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Figure 3.4 Westem blot analysis of Mas proton-oncogene expression in 
various cells lines. Protein (30 i^g) harvested from A431 cells, L929 cells, and 
mouse fibroblasts cells. Pre-stained protein markers are shown on lane M. 
Membranes were probed with a polyclonal anti-Mw Ab (1:1000 dilution) in 
the absence (panel A) and presence O a^nel B) of the Mas peptide (2 ^ig/ml) 
which was used to raise the anti-Mas antibody in rabbit. The close triangle 
represent the desired immunoreactive bands of48 and 72 kDa. 
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By adding the Mas peptide which was used to raise the mU-Mas antibody in 
rabbit, both of the immunoreactive bands (48 and 72 kDa) were blocked. It 
suggested that the anti-Mas antibody was specific to the Mas peptide, therefore 
those immunoreative bands were not due to non-specific binding of anti-Mos 
antibodies. Sequence analysis indicated that the Mas encodes a protein with a 
calculated molecular mass of 37 kDa with three glycosylation sites on the N-
terminal end. Moreover, a 72 kDa protein was detected by in vitro translation 
(Cheung W. T., unpublished data). These findings strongly support the idea that 
both the 48 and 62-72 kDa immunoreactive bands were the glycosylated forms 
of Mas protein. They suggested that most of the cell lines (Figure 3.2, 3.3 & 
3.4) do express at least two Mas-YikQ immunoreactive bands (48 and 72 kDa). 
Only the mouse fibroblasts (Figure 3.4) expresses the 48 kDa protein alone. 
As most of the cell lines do express Mas protein endogenously, transient and 
stable over-expression of Mas oncogene were used to evaluate the differences 
between the parental, Mas transfected and mock vector transfected cells. 
Optimization of transfection was done by adding different amount of 
lipofectamine together with a pSEAP2-control vector (from Clontech) which 
encodes a secretary form of the alkaline phosphatase that can be detected by 
fluorescent substrate, such as 4-methylumbelliferyl phosphatase (MUP). Results 
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Figure 3.5 Fluoresence assay of transfection optimization by using 
lipofectamine. MH3T3 cells were seeded at 2xl0^ per well and 2|iig 
SEAP-Control vector was added per well. Lipofectamine was added from 
0 to 20 [il Cells were incubated at 37°C for 5 hr with 5 % CO2. 
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As mouse fibroblasts are primary cells and they die after three to five passages, 
mouse fibroblasts are not suitable for the transient transfection. Initially, Cos-7 
cells were used for transfection study as they are commonly used for 
mammalian protein expression. Results from McGillis and co-workers (1989) 
showed that Mas transfected Cos-7 cells expressed a functional angiotensin II 
2 j 
receptor with an increase in intracellular Ca when stimulated by angiotensin 
11. Protein was harvested 24 hr post transfection, and unexpectedly there was no 
difference between the parental and Mas oncogene transfected cells (Figure 
3.6)�To confirm the lack of difference 'mMas expression is not due to the use of 
excess antibodies, another Western blot was probed with serial dilutions of anti-
Mas antibodies. Protein was harvested 24 hr post transfection and the antibodies 
were varied from 1000 to 160000 fold (Figure 3.7). Even though the lowest 
amount of antibodies (1:160000 x dilution) was used, no difference between the 
parental and Mas transfected Cos-7 cells was not detectable. Results implied 
that the Cos-7 cell line was not suitable for the transient expression of Mas 
oncogene with the mammalian expression vector pOPRSVI. 
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Figure 3.6 Westem blot analysis of Mas proto-oncogene 
expression in Cos-7 cells. Protein (30 ^ig) was harvested 24 hr post 
transfection of Mas oncogene. Mock vector that lack of Mas 
oncogene insert. Pre-stained protein markers are shown on lane M. 
The blot was probed with the polyclonal anti-A/".s. Ab (1; 1000x 
dilution). The close triangle represent the desired immunoreactive 
bands o f 4 8 a n d 72 kDa. 
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Figure 3.7 Western blot analysis the expression of Mas proto-
oncogene in Cos-7 cells. Protein was harvested 24 hr post transfection 
with full length Mas clone (lane 1，3，5, 7 & 9) and with mock vector 
alone (lane 2，4，6, 8 & 10). Pre-stained protein markers are shown on 
lane M. The blot was probed with polyclonal anii-Mas Ab (l:16000x 
dilution) (lane 1 & 2)，(l:80000x dilution) (lane 3 & 4), (l:4000x 
dilution) (lane 5 & 6)，(l:2000x dilution) (lane 7 & 8)，and (l:lOOOx 
dilution) (lane 9 & 10). The close triangle represent the desired 
immunoreactive bands of48 and 72 kDa. 
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Since result from Figure 3.2 showed that PC12 cells did not express the 72 kDa 
immunoreactive band when probed with the mii-Mas antibodies, it is likely that 
PC12 cells did not endogenously express large amount of Mas protein. 
Therefore, Western blots were performed in PC12 cells transfected with Mas 
oncogene and mock vector alone. Membrane protein was harvested at 24 hr and 
48 hr post transfection to compare the expression difference of Mas protein in 
parental, Mas transfected and mock vector transfected PC12 cells (Figure 3.8). 
Though the Mas specific immunoreactive bands was 48 and 62-72 kDa were 
obtained, there was no significant increase in the expression of Mas protein in 
Mas transfected cells when compared to the parental and mock vector 
transfected PC12 cells. 
ks>Mas oncogene was isolated from a tumorigenicity assay with MH3T3 cells, 
transient expression of Mas was fiirther examined in that cell (Figure 3.9). 
However, results show that there was no difference in the transient expression 
oiMas protein (48 and 62 kDa) in parental, Mas transfected and mock vector 
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Figure 3.8 Western blot analysis of Mas proto-oncogene transient 
expression in PC12 cells. Protein (30 路）was harvested 12 hr (lane 1, 2 & 3) 
and 24 hr (lane 4, 5 & 6) post transfection ofMas oncogene (lane 2 & 5)，mock 
vector alone (lane 3 & 7) and parental cells (lane 1 & 4). Pre-stained protein size 
markers are shown on lane M. The blot was probed with a polyclonal anti-Mw 
Ab (l:lOOOx dilution) in the absence (panel A) and presence (panel B) ofthe 
Mas peptide (2 i^g/ml) which was used to raise the anti-Mas antibody in rabbit. 




As transient transfection of various cell lines by Mas DNA did not show the 
successful expression of Mas protein. Stable cell line was established to 
evaluate the expression of Mas protein. Expression of Mas gene product has 
been shown to induce a loss of contact inhibition in Balb3T3 and MH3T3 cells 
(Andrawis et al., 1992). In this experiment, two related cell lines, Swiss3T3 and 
MH3T3 were used. Stable transfection of Mas oncogene was established in 
both Swiss3T3 and Nffl3T3 cells (Figure 3.10 and 3.12). Protein blot of 
parental and Mas stably transfected Swiss3T3 cells was probed with serial 
dilutions of anti-Mas> antibodies in order to detect minute amount changes in the 
expression of Mas protein. By comparing the immunoreactive bands between 
parental and Mas transfected cells, one of the immunoreactive band (48 kDa) 
was obviously increased in Mas transfected Swiss3T3 cells when compared to 
the parental cells. These findings were consistent in all the dilutions of anti-Mos 
antibodies. Stable expression of Mas and Rac oncogene in MH3T3 cells has 
been reported to display a change in the morphology (Zhon et al., 1998). 
However, there was no change in the morphology of the Mas and mock vector 
transfected cells when compared to the parental cells (data not shown). 
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Figure 3.9 Western blot analysis of Mas proto-oncogene transient 
expression in NIH3T3 cells. Protein (30 ^ig) was harvested 24 hr post 
transfection of Mas oncogene, mock: vector alone and parental cells. Pre-stained 
protein markers are shown on lane M. The blot was probed with the polyclonal 
anti-Mw Ab (l:lOOOx dilution) in the absence 0>anel A) and presence ^>anel B) 
of a Mas peptide (2 ^ig/ml) which was used to raise the anti-Mw antibody in 
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Figure3.10 Western blot analysis the stable expression oiMas 
proto-oncogene in Swiss3T3 cells. Cells were transfected with either 
full length Mas clone or mock vector alone and growth in selective 
medium with 400 ^g G418 for 2 weeks. Multiple G418 resistant 
colonies (>1000) were pooled together and grown in medium without 
G418. Protein (30 mg) was harvested from stable transfection with Mas 
oncogene (lanes 1, 3, 5, 7) and parental cells (lanes 2，4, 6，8). Pre-
stained protein markers are shown on lane M. The blot was probed 
with the polyclonal anti-Mw Ab (l:8000x dilution) (lanes 1 & 2)， 
(l:4000x dilution) (lanes 3 & 4)，(l:2000x dilution) (lanes 5 & 6)， 
(l:lOOOx dilution) (lanes 7 & 8). The close triangle represent the 
desired immunoreactive bands of 48 and 72 kDa. 
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In contrast, by comparing the morphology of the Mas stably transfected (Figure 
3.11 panel B)，MH3T3 cells (Figure 3.11 panel A) and mock vector transfected 
MH3T3 cells (Figure 3.11 panel C), morphology of the Mas oncogene stably 
transfected cells were changed to ovoid shaped. However, there was no changes 
in the morphology in parental and mock vector transfected cells, and they were 
still in elongated spindle-shaped. In Western blot analysis of multiple G418 
resistance colonies, the expression of Mas protein (immunoreactive band 
48kDa) was increase significantly in Mas oncogene stably transfected cells 
when compared to the parental and mock vector stably transfected cells (Figure 
3.12). Also, the 62 kDa immunoreactive band has the same intensity in parental 
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Figure 3.11 Phase-contrast photomicrographs of confluent NIH3T3 cells 
with 20x magnification. (A) NIH3T3 cells. Most cells were elongated and 
spindle-shaped fibroblasts. (B) Mas stably transfected NIH3T3 cells. Most 
cells were ovoid shaped. (C) Mock vector stably transfected NIH3T3 cells. 
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Figure 3.12 Westem blot analysis of Mas proto-oncogene expression in 
NIH3T3 cells. Protein (30 jug) was harvested from cells stably transfection 
with Mas oncogene, mock vector alone. Cells were grown in selective 
medium with 400 mg G418 for 2 weeks. Multiple G418 resistance colonies 
(>100) were pooled together and grown in medium without G418. Pre-
stained protein markers are shown on lane M. The blot was probed with the 
polyclonal anti-Max Ab (l:lOOOx dilution) in the absence (panel A) and 
presence (panel B) of a Mas peptide (2 ^ig/ml) which was used to raise the 
^nXi-Mas antibody in rabbit. The close triangle represent the desired 
immunoreactive bands of 48 and 62 kDa. 
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In order to evaluate whether expression of Mas gene will enhance the 
expression of the endogenous angiotensin II, quantitative RT-PCR was 
performed in parental cells and cells stably transfected with Mas and mock 
vector. The sequence of the 100 bp deleted ATiAR was identical to the cloned 
ATiAR (Iwai et al., 1991) (Figure 3.13), except that there were two nucleotide 
changes at nucleotide 1209 from T to C and an extra C nucleotide at nucleotide 
1387. 
Quantitative RT-PCR of ATiA R was performed in Mas oncogene (Figure 3.14 
panel B) and mock vector (Figure 3.14 panel C) stably transfected cells and 
MH3T3 cells (Figure 3.14 panel A). Results from quantitative RT-PCR of 
ATiAR show that the expression of ATiAR mRNA in parental and mock vector 
transfected cells was around 20 ng in 5 i^g RNA (Figure 3.12 panel A and C), in 
Mas transfected cell line it was around 51 ng in 5 i^g RNA (Figure 3.12 panel 
B). The expression of ATiAR 'mMas transfected cell lines was increased by 2.5 
folds when compared to the parental and mock vector transfected cell lines. 
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Query: 994 tgtgcttttcttcttcttttcctgggtcccccaccaaatattcactttcctggatgtgct 1053 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 1 tgtgcttttcttcttcttttcctgggtcccccaccaaatattcactttcctggatgtgct 60 
Query: 1054 gattcagctgggcgtcatccatgactgtaaaatttctgacatcgtggacactgccatgcc 1113 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I ！ I I I I I I I I I I I I I I I I 
Sbjct: 61 gattcagctgggcgtcatccatgactgtaaaatttctgacatcgtggacactgccatgcc 120 
Query: 1114 catcaccatctgcatagcgtattttaacaactgcctgaaccctctgttctacggctttct 1173 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 121 catcaccatctgcatagcgtattttaacaactgcctgaaccctctgttctacggctttct 180 
Query: 1174 ggggaagaaatttaaaaagtatttcctccagctcctgaaatatattcccccaaaggccaa 1233 
I I I I I I I I I I I I I I I I I I 1 I I I I I I i I I i I I I I I I I I I I I I I i I I I I I I i I I I I I I I I I 
Sbjct: 181 ggggaagaaatttaaaaagtatttcctccagctcccgaaatatattcccccaaaggccaa 240 
Query: 1234 gtcccactcaagcctgtctacgaaaatgagcacgctttcttaccggccttcggataacat 1293 
I I I I I 1 I I I I I I I I I I 1 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 241 gtcccactcaagcctgtctacgaaaatgagcacgctttcttaccggccttcggataacat 300 
Query: 1294 gagctcatcggccaaaaagcctgcgtcttgttttgaggtggagtgacaggttcaaagcac 1353 
I I I I I i I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 301 gagctcatcggccaaaaagcctgcgtcttgttttgaggtggagtgacaggttcaaagcac 360 
Query: 1354 actggcaatgtaatgccctgacagaagccaggg-agcctctgactaaatggcttacgacc 1412 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 361 actggcaatgtaatgccctgacagaagccagggcagcctctgactaaatggcttacgacc 420 
Query: 1413 aaaggaccattcaccc 1428 
I I I I I I I I I I I I I I I I 
Sbjct: 421 aaaggaccattcaccc 436 
Figure3.13 Alignment of the PCR prodcut of ATiAR (Sbjct) with the cloned 
ATiAR sequence (Query) in GenBank with an accession no. M74054 by using Blast 
Search 2.0. A partial length RT-PCR product of ATiA R (450 bp) sequence from rat 
pancreas was obtained with the forward primer (5'-TGG GCA TTG TGC TTT TCT 
TC-3，) and reverse primer (5'-GGG TGA ATG GTC CTT TGG TC-3'). Though there 




Figure3.14 Quantitative RT-PCR analysis of angiotensin type 1 receptor 
expression in MH3T3 cells (panel A), Mas stably transfected MH3T3 cells 
(panel B) and mock vector stably transfected MH3T3 cells (panel C). Total 
RNA (5 i^g) extracted from cells were reverse transcripted into cDNA. cDNA 
(1 pil, 16 X dilution) was co-amplified with an internal standard (350 bp) of 
which final quantity was 10 ng (lane 1)，4 ng (lane 2), 1.6 ng (lane 3), 0.64 ng 
(lane 4)，0.25 ng (lane 5), 0.1 ng (lane 6) and 0.04 ng (lane 7). 100 bp DNA 
markers were shown on lane M. 
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In protein level, Western blot (Figure 3.12) showed an the increased expression 
of Mas protein in Mas stably transfected MH3T3 cells as compared to the 
parental and mock vector stably transfected cells. In mRNA level, quantitative 
RT-PCR of Mas was performed in Mas oncogene (Figure 3.15 panel B) and 
mock vector (Figure 3.15 panel C) stably transfected and MH3T3 cells (Figure 
3.15 panel A). Results from quantitative RT-PCR with Mas show that the 
expression of Mas mRNA in parental and mock vector transfected cell lines 
was around 12.88 and 32 ng in 5 i^g RNA (Figure 3.15 panel A and C), 'mMas 
transfected cell line was around 80 ng in 5 i^g RNA (Figure 3.15 panel B). The 
expression of Mas in Mas transfected cell lines was 6 and 2.5 folds increased 
when compared to the parental and mock vector transfected cell lines. These 
results were agreed with the previous finding in Figure 3.12. 
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Figure 3.15 Quantitative RT-PCR analysis ofMas oncogene expression 
in MH3T3 cells (panel A), Mas stably transfected MH3T3 cells (panel B) 
and mock vector stably transfected MH3T3 cells (panel C). Total RNA (5 
jj,g) extracted from cells were reverse transcripted into cDNA. cDNA (1 
pil, 8 X dilution) was co-amplified with an internal standard (450 bp) of 
which final quantity was 0.1 pg (lane 1), 0.02 pg (lane 2), 4 x 10'^  pg 
(lane 3), 8 x 10"^  pg (lane 4), 1.6 x 10'^  pg (lane 5), 3.2 x 10"^  pg (lane 6) 
and 6.4 x 10'^  pg (lane 7). 100 bp DNA markers were shown on lane M. 
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In the screening for the endogenous expression of Mas protein, two dominant 
immunoreactive bands (48 and 72 kDa) were detected in parental cell lines Cos-
7, ECV304, AR4-2J, AR4-ff>, A431& L929 cells. While other cell lines (AlO & 
mouse fibroblasts) did not exhibit the 62-72 kDa immunoreactive band was not 
observed clearly but the 48 kDa immunoreactive band was observed. In all 
these cell lines, the blot were probed in the absence and presence of Mas 
peptide and the immunoreactive bands (48 and 62-72 kDa) obtained in the 
absence of Mas peptide were Mas specific. The Mas protein is expected to be 
37kDa (Hanely et al., 1990) and previous findings demonstrated that the Mas 
sequence contains three glycosylation sites on the N-terminal end (Young et al., 
1986). Moreover, results from in vitro translation showed that a 72 kDa protein 
was detected (Cheung W. T., unpublished data). These findings strongly support 
the idea that both the 48 and 62-72 kDa immunoreactive bands were the 
glycosylated form of Mas protein. The molecular mass of the 62-72 kDa 
immunoreactive band vary in different cell lines. For instance, the 
immunoreactive band is 62 kDa in MH3T3 cells but 72 kDa in AR4-2J cells. 
Difference may be due to different glycosylation in different cell lines as 
example by the AT2 receptor (Servant et al., 1994). However, possibility cannot 
be excluded that the size difference may be resulted from different size markers 
were used in those experiments. Other immunoreactive bands with molecular 
mass > 102 kDa were obtained inconsistently in the blot when probed with the 
anti-Moy antibodies. This may be due to non-resolved protein aggregation. 
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Results from all the cell lines suggested that different cell lines express Mas 
differently. For examples, mouse fibroblasts does not express the 62-72 kDa 
glycosylated form of Mas protein. The primary cell lines of mouse fibroblasts 
were not suitable for the transient transfection because their life span were only 
few passages. On the other hand, PC12 cells which required a very large 
amount of lipofectamine for the transient transfection and their transfection 
efficiency was very low (data not shown). 
Results from transient transfection of Cos-7 cells showed that the expression of 
Mas protein was the same compared to that of the cells transfected by a mock 
vector and the parental cells even with 160000 fold dilution of anti-Mas 
antibodies to detected the minute amount of the expression of Mas protein. 
There was no Mas difference in the oncoprotein level in the transient 
transfected MH3T3 cells and PC12 cells. It is of interest to note that previous 
transient transfection in different cells determined only the intracellular calcium 
level and inositol phosphate level but not theMos* protein level. 
Mas stably transfected cell lines were established in Cos-7 cells (data not 
shown), Swiss3T3 cells and MH3T3 cells. In the Mas and mock vector stably 
transfected cell line of Cos-7 cells, no detectable changes in the expression of 
Mas protein in Mas or mock vector stable cells when compared to the parental 
cells. However, in RT-PCR analysis the expression o^Mas oncogene in Mas 
stably transfected Cos-7 cells showed that there was significant increase in the 
Mas stably transfected cells when compared to the parental and mock vector 
transfected cells (Data not shown). Therefore, Cos-7 cells express, if any, very 
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low amount oiMas protein. For Swiss3T3 cells, the Mas stably transfected cells 
showed significantly increased Mas protein level when compared to the 
parental cell line. Also, these finding was not observable in the transient 
transfection of Mas oncogene in Swiss3T3 cells. However, there was no 
morphology changes observed between the Mas stably transfected and the 
parental cells. 
For MH3T3 cells, transient transfection o^Mas oncogene and mock vector did 
not produce any difference in the expression of Mas protein. However, in stable 
transfection with Mas oncogene and mock vector, there was a significantly 
increase of the expression of Mas protein while that of the parental cells and 
cells transfected by a mock vector are the same. In the Mas stably transfected 
MH3T3 cells, morphology changed from elongated spindle shape to ovoid 
shape. The morphology of the parental and the mock vector stably transfected 
cell were remained elongated spindle shape. Our finding agrees with Zhon and 
co-workers (1998) that there were morphology changes of stable expression 
Mas in MH3T3 cells. Moreover, we have observed that at the confluence stage, 
the parental and the mock vector transfected cells exhibited a quiescent state 
while the Mas transfected cells continued to grow even in the absence of serum 
(data not shown). These results also agree with the finding from Andrawis and 
co-workers (1992) that the stable expression ofMas in both Balb3T3 cells and 
MH3T3 cells were result in the lost of contact inhibition and the Mas 
transfected cells are capable to growth in the absence of serum. Andrawis and 
co-workers (1992) suggested that the growth of Ma^-transfected cells in the 
absence of serum ,is compatible with a hypothesis that the 3T3 cells are 
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producing an endogenous agonist for the Mas receptor. Even both MH3T3 cells 
and Swiss3T3 cells have established the Mas stably transfected cell lines and 
both stable cell lines can express the Mas protein, the Swiss3T3 cells did not 
have such morphology changes. Also, in Mas stably transfected Cos-7 cells, 
there was no express in extra of Mas protein and morphology changes was not 
observed. These results suggest that expression of Mas oncoprotein is tightly 
regulated, and signal transduction oiMas oncogene is cell-type specific. 
Our results suggested that stable expression oiMas oncogene in MH3T3 cells 
does enhance the expression of angiotensin receptor, which might explain partly 
that transient expression of Mas oncogene enhances the cellular response to 
angiotensin, such as the raise of calcium ion level and inositol phosphate level 
(Ambroz et al., 1991, Jackson et al., 1989，Poyner et al., 1990). 
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Chapter 4 Cloning of ATiA Receptor Promoter 
4.1 Introduction 
Previous data in Chapter 3 has confirmed that stable expression of Mas 
oncogene in MH3T3 cells does enhance the expression of the ATiA Receptor 
with the morphology changed from elongated spindle shape to ovoid shape. 
Expression of angiotensin receptor was known to be regulated by various 
regulating elements. Functional analysis of the 5，flanking region of the ATiA 
receptor revealed that it has at least three positive regulatory elements, P1 (-560 
to 489), P2 (-331 to -201), P3 (-201 to -61), and one negatively regulatory 
element (-489 to -331) located in the 980 base pairs upstream of the coding 
sequences. To evaluate whether Mas up-regulated angiotensin expression via 
interacting with the conserved cis-regulating elements in the angiotensin 
promoter, a reported gene (secreted form of alkaline phosphate) is put under the 
control ofpromoter of angiotensin receptor. Expression of the reporter gene and 
angiotensin receptor is analyzed in the absent or present oiMas expression. 
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4.2 Materials and Methods 
4.2.1 Materials 
PCR-TRAP Cloning System and PCR Cloning Kit (blunt end) were obtained 
form GenHunter and Boehringer Mannheim, respectively. The LacSwitch™ II 
Inducible Mammalian Expression System and Great EscAPe™ SEAP Reporter 
System 2 were obtained from Stratagene and Clonetech. Expand™ Long 
Template PCR System were obtained from Boehringer Mannheim. 
4.2.2 Genomic DNA Extraction from Rat Pancreas 
Genomic DNA was extracted from rat pancreas (50 mg) by using 1 ml DNAzoL 
as described in section 2.2.11. 
4.2.3 Nest PCR Amplification of 3.2, 2.8 and 1.4 kb AT!A Receptor 
Promoter 
In the first round ofPCR, the PCR reaction mixture contained 1 x PCR buffer 
with 1.75 mM MgCl2, 0.5 mM dNTP, 1 i^M each of forward and reverse 
primers, 0.5 i^g of genomic DNA template and 2.5 units of Expand Long™ 
Template enzyme mixture in a final volume of 50 i^l. The PCR primers were 
designed base on the reported sequence of rat angiotensin receptor promoter 
(Takeuchi et al., 1993). The forward primer (ATiA RP-F1) is from nucleotide 1 
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to 25 (5'-ACT AGT TTG ATT TTC ATT TCT ACA GT-3') and reverse primer 
(ATiARP-R4) is complementary to sense sequence from 3427 to 3451 bp (5'-
ACT CTG AT CAG ATG TGG GTA CAA G-3'). 
The standard reaction mixture was subjected to a PCR condition as follows; 
after additional denaturation at 94 °C for 3 min, the mixture was subjected to 30 
cycles of denaturation at 94 °C for 30 sec, annealing at 54 °C for 45 sec and 
elongation at 68 ®C for 3 min, and a final prolong elongation at 68 ^C for 7 min. 
The PCR products was separated on a 0.7% agarose gel at constant voltage (120 
volts) with and the desired fragments were purified by QIAquick Gel Extraction 
Kit. 
In the second round PCR, the PCR reaction mixture and the PCR condition was 
the same as in the first round PCR, except the template was twenty-five folds 
dilution (1 i^l) of the first round PCR product. 
For 3.2 kb PCR fragment in the second round PCR, PCR primers were designed 
base on the reported sequence of rat ATiA receptor promoter (Takeuchi et al., 
1993).The forward primer (ATiA RP-FlC) is from nucleotide 1 to 25 except the 
first 10 base in the 5’ end which is an additional added restriction site Mlu I (5'-
AAC GAC GCG TAC TAG TTT GAT TTC ATT TCT ACA GT-3') and the 
reverse primer (ATiA RP-R2B) is complementary to sense sequence from 




For 2.8 kb PCR fragment in the second round PCR, PCR primers were designed 
base on the reported sequence of rat ATiA receptor promoter (Takeuchi et al., 
1993).The forward primer (ATiA RP-F7) is from nucleotide 512 to 531 (5'-
CAG GCG ACG CGT GAG GGG AAT AAG AGG AAG G-3，) and the reverse 
primer ATiA RP-R2B was mentioned as above. The underlined sequences in the 
forward and reverse primers represent the additional added endonuclease 
restriction site Mlu I and Bgl 11, respectively. 
For 1.4 kb proximal portion of PCR fragment in the second round PCR, PCR 
with forward primer (ATiA RP-FlC) as mentioned in section 4.2.3. The reverse 
primer (ATiA RP-R3P) is complementary to sense sequence from nucleotide 
1437 to 1455 (5'-GTT TCG ATA TCT GCC TTG TCA AGC-3'). The 
underlined sequences in the reverse primer represent the additional added 
endonuclease restriction site EcoRV. 
4.2.4 PCR Amplification of 2.2 kb Aproximal Portion ofATiA Receptor 
Promoter 
The first round PCR amplification mixture and condition is the same as 
described in section 4.2.3. Forward primer (ATiARP-F12P) sequence is from 
nucleotide 1364 to 1387 (5'-GCA AAG ATT TAA TTA ACA TGC CTG-3') 
and the reverse primer ATiA RP-R2B is as mentioned in section 4.2.3. The 
underlined sequences in the forward primer represent the additional added 
endonuclease restriction site PacI. 
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The second round PCR mixture was the same as described in section 4.2.3. The 
standard reaction mixture was subjected to a PCR condition as follows: after 
additional denaturation at 94 ^C for 3 min, the mixture was subjected to 30 
cycles of denaturation at 94 °C for 30 sec, annealing at 55 ^C for 45 sec and 
elongation at 68 °C for 2 min, and a final prolong elongation at 68 ^C for 7 min. 
The PCR products was separated on 0.7% agarose gel at a constant voltage (120 
volts) and the desired fragments were purified by QIAquick Gel Extraction Kit. 
4.2.5 Construction of PCR Fragment of Angiotensin Receptor Promoter 
into Various Vectors 
V < 
4.2.5.1 pSEAP2-Basic 
PCR fragment of angiotensin receptor promoter and the plasmid vector 
pSEAP2-Basic were digested with 10 units of restriction endonucleases Mlu I 
and Bgl II, then incubated at 37 °C for 2 hrs. Afterwards, the digested plasmid 
vector was purified by QIAquick Gel Extraction Kit, while the digested PCR 
fragment was purified by QIAquick PCR Purification Kit. The PCR fragment 
and vector were mixed together in 5 to 1 molar ratio to made up a reaction 
mixture containing about 0.1 i^g DNA, T4 DNA ligase (lU per mg DNA) and 
ligation buffer (1 x in final concentration) in a final volume of 20 i^l. Finally, 
the mixture was incubated at 16 °C overnight. The positive clone was screened 
by both direct PCR analysis and minipreps with enzyme digestion. 
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4.2.5.2 pBluescript® II SK Vector 
The method ofblunt end ligation of insert into plasmid vector was described in 
section 2.2.13. 
4.2.5.3 PCR Cloning Kit (pCAP^ vector) 
The method of blunt end ligation of insert into PCR cloning kit was mentioned 
in section 3.2.5.5. 
4.2.5.4 PCR-TRAP Cloning System 
For blunt end ligation, the ligation mixture contained the insert-ready PCR -
TRAP® Vector (2 i^l), 10 x ligase buffer (2 i^l), PCR product (5 i^l), T4 DNA 
ligase (1 pil) and made to a final volume of 20 i^l. Finally, the mixture was 
incubated at 16 °C overnight. The positive clone was screened by both direct 
PCR analysis and restriction fragment analysis. 
For direct PCR, each colony was picked by a sterile toothpick and then 
transferred to 50 i^l of a colony lysis buffer (provided by the manufacturer). 
After that the tube was incubated at 95 °C for 10 min. The tube was then spined 
at 15,800 X g for 2 min and the supernatant was transferred into a clean tube. 
The PCR reaction mixture contained 1 x PCR buffer, 20 i^M dNTP, 0.2 i^M 




3' and reverse primer (Rgh) with sequence 5'-CTG CGC TTG CTT CGT TG-
3', 2 i^l of colony lysate and lU of Taq DNA polymerase mixture in a final 
volume of 20 i^l. Primers, 10 x PCR buffer and dNTP were provided by the 
manufacturer. 
The standard reaction mixture was subjected to a PCR condition as follows: 
after additional denaturation at 94 °C for 3 min, the mixture was subjected to 30 
cycles of denaturation at 94 ^C for 30 sec, annealing at 52 °C for 40 sec and 
elongation at 72 °C for 2 min, and a final prolong elongation at 72 °C for 7 min. 
4.2.6 Direct PCR Analysis 
For direct PCR analysis, cells from a transformant colony was removed by 
using a sterile toothpick and then transferred into a sterile reaction vial. The 
reaction vial contained 100 i^l of sterile water and it was incubated at 100�C for 
5 min. After that reaction tube was subjected to a short centrifugation and a 5 [d 
aliquot of the supernatant was used for direct PCR reaction. 
The design of the forward and reverse primers was based on the pSEAP2-Basic 
vector sequence. The forward primer (pSEAP2B-Fl) sequence is from 
nucleotide 4581 to 4600 (5'-CAT AGC CTC TCC ATC AAA AC-3,) and 
reverse primer (pSEAP2-R2) is complementary to sense sequence from 
nucleotide 141 to 160 (5'-GTC CGG GTT CTC CTC CTC AA-3'). The 
standard reaction mixture was subjected to a PCR condition as follows: after 
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additional denaturation at 94 °C for 3 min, the mixture was subjected to 30 
cycles of denaturation at 94 °C for 30 sec, annealing at 58 °C for 45 sec and 
elongation at 68 °C for 3 min, and a final prolong elongation at 68 °C for 7 min. 
4.2.7 Autosequencing of PCR Fragment of ATiA Receptor Promoter 
The method of autosequencing was mentioned in section 2.2.15.2. Primers used 
for auto sequencing of ATiARP-F7/R2B (2.8 kb) were listed as in table 4.1. The 
nucleotide number listed on the primer sequence represent the nucleotide 
number listed on the original sequence of type 1 angiotensin receptor in 
GenBank with an accession no. S66402. The underlined sequences in the 
forward (F) and reverse (R) primers represent the additional added 
endonuclease restriction site Mlu I and Bgl II，respectively. 
Primers for ATiARP-F12P/R2B (2.2 kb) PCR Fragment were listed as in Table 
4.2. The nucleotide number listed on the primer sequence represent the 
nucleotide number listed on the original sequence of the type 1 angiotensin 
receptor in GenBank with an accession no. S66402. The underlined sequences 
in the forward (F) and reverse (R) primers represent the additional added 
endonuclease restriction site Mlu I and Bgl II, respectively. 
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Table 4.1 List of primers name and sequences used for autosequencing of ATiA 
RP-F7/R2B (2.8 kb) PCR fragment. 
Primer Name Sequence 
ATiARP-F7~5,-CAG GCG ACG CGT''^GAG GGG AAT AAG AAGAAG Gs.i-3, 
ATiA RP-F8~~ y-TGG ACG ACG CGT^^^^TC CTT CTGTGG CTT CTA CC"'^-3' 
ATiA R P - F 9 ^ 5,-ATA CCG ACG CGT' ' 'CAG ACT GGC TAC ATG GGA TTG"''-3^ 
ATi A RP-FlQ 5，-TGG GCG ACG CGT^''GGC AGA TGG TGT TTA TGT GCC C ' " ' - 3 ' ^ 
ATi A RP-F11 5,-TAA ACG ACG CGT^GCT CGA GCA ACG TGT AAA CTA G"''^-3 ’ 
ATi A RP-R2B 5,-GAA GAT CT''''GGT ACC GGC CTC GGC CAC CCC GGT C''^'-3,~~ 
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Table 4.2 Lists of primers name and sequences used for autosequencing of 
ATiARP-F12P/R2B (2.2 kb) PCR fragment. 
Primer Name Sequence 
A T i A R P - F 9 ~ 5,-ATA CCG ACG CGT^''CAG ACTGGC TAC ATG GGA TY&' ' -3 ' 
ATi A RP-FlQ 5^-TGG GCG ACG CGT'''GGC AGA TGG TGT TTA TGT GCC C^''-3^~~ 
ATiA RP-F15 5 - ' 'GCA CCA TAT ATC CAC CAT A C _ - 3 ' 
ATiA RP-F16 5,，GGG CTC AGG CGA GAG AGC C _ - 3 , 
ATiA RP-F17 5 -i629ccC CCG CCC CGC CCT GAG ACC C ^ - 3 , 
ATiA R P - R 4 ^ 5 , - i � C A AAG ATT TAA CAT GCC TGT^'' '-3' 




4.3.1 PCR Cloning ofATiA Receptor Promoter 
With the use of forward primer ATiARP-FlC and reverse primer ATiA RP-R2B, 
a 3.2 kb ATiA receptor promoter was amplified from rat pancreatic genomic 
DNA (Figure 4.1 lanel). Subsequently, nest PCR was used to generate the 2.8 
(Figure 4.1 lane2) and 1.4 kb promoter fragment. The 2.8 kb PCR fragment was 
sequenced and the sequence was shown in Figure 4.2. From the sequence data, 
there are 38 nucleotides mismatch in sequence when compared to the promoter 
sequence in the GenBank with an accession no. S66402. The first 18 
nucleotides mismatch was found from 755 to 1138 bp. While the rest 20 
nucleotides mismatch was found from 1574 to 3077 bp. Since the PCR 
fragment of 2.8 kb was the second round PCR product, therefore, the 
percentage of getting the mismatch nucleotides are more easy than those in the 
first round PCR. Moreover, the PCR product is 2.8 kb which is a quite long 
fragment obtained by PCR method. 
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M 1 2 
l k b - ^ ^ 9 H H 
Figure 4.1 3 1 kb PCR fragment (lane 1) and 2.8 kb PCR 
fragment (lane 2) of AT^^ receptor promoter by PCR method. 
1 kb DNA markers were shown on lane M. 
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Query: 546 agtggcttgcaaccccataaaaacaacaatgccaaccaacgagagcttccagggactaaa 605 
I I I I I I I I I I I I I I I I I I 1 I I 1 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 1 agtggcttgcaaccccataaaaacaacaatgccaaccaacgagagcttccagggactaaa 60 
Query: 606 ccactaccataagactatacattgactgacccagggctccaactgcatatgtagcagaga 665 
I I I I I I I I I I I I I 1 I I I I I I I I I I I 1 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 61 ccactaccataagactatacattgactgacccagggctccaactgcatatgtagcagaga 120 
Query: 666 acagcctttttggggcaccagtggaaggggaagcccttagttctgccaaggttggacccc 725 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 121 acagcctttttggggcaccagtggaaggggaagcccttagttctgccaaggttggacccc 180 
Query: 726 cagtgcaggggactgttgaggtgggataatgaggggcagatgggggggaacacccttatg 785 
I 1 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I Sbjct: 181 cagtgcaggggactgttgaggtgggataaggaggggcagatgggggggaacacccttatg 240 Query: 786 gggcggggcggggctagggg-ctatggacaggaaactgggcaagggcataaacatttgaa 844 
I I I 1 1 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 241 gggaggggaggggatagggggctatggacaggaaactgggaaagggaataacattttgaa 300 
Query: 845 a-gtaaataaagaaatatatccaacaaaccaaacaaactgtgttttcttga-ctgttttt 902 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 1 I I I I I I I I 1 I I I I I I I I I I I I I 
Sbjct: 301 atgtaaataaagaaatatatccaacaaaccaaacaaactgtgttttcttgaactgttttt 360 
Query: 903 tccaagttatttatgttttggaaattaagcttataatttaataatttatataatacacgt 962 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 361 tccaagttatttatgttttggaaattaagcttataatttaataatttatataatacacgt 420 
Query: 963 tatatgttaatactatatgttatgccatacatcatatgtcaaatgtcatagattatatgc 1022 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 1 I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 421 tatatgttaatactatatgttatgccatacatcatatgtcaaatgtcatagattatatgc 480 
Query: 1023 tgtatgttacatttcacacgttatatgtcaaa-tgtcatgtt-atataatttttctgtat 1080 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 481 tgtatgttacatttcacacgttatatgtcaaaatgtcatgtttatatactttttctgtat 540 
Query: 1081 atcacatattatatataattaaataatgtatatgttttggaaattatgtatagctggaaa 1140 
I I I I 1 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I i I I I i I I ! I I I I I i i I I 
Sbjct: 541 atcacatattatatataattaaataatgt-tatgttttggaaattatttata-ctgcaaa 598 
Query: 1141 aaatttctctcttctgtgggcttctacctcactcagttggctgtttctgtttccctccct 1200 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 599 aaatttctctcttctgtgggcttctacctcactcagttggctgtttctgtttccctccct 658 
Query: 1201 gtgcagaagacctttatggggtctcatttatcagttgttggcctctattcggaggggaac 1260 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 659 gtgcagaagacctttatggggtctcatttatcagttgttggcctctattcggaggggaac 718 
Query: 1261 agaattcaggaagccctttcctgaacttgtctcttgtatgtcactgtttttgttctcttc 1320 
I I I I I I I I 1 I I I I I I I I I 1 I I I I I I I I 1 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 719 agaattcaggaagccctttcctgaacttgtctcttgtatgtcactgtttttgttctcttc 778 
116 
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Query: 1321 cagcagagtttcatactagaaaaccacctgagtttatatctttgcaaagatttaattaac 1380 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 779 cagcagagtttcatactagaaaaccacctgagtttatatctttgcaaagatttaattaac 838 
Query: 1381 atgcctgtgacttttcacaacatcaggatttattggataacaacaaattccttgatagct 1440 
I I I I I I I 1 I I I I I I I I I I I I I I I I I I I I I I I 1 I I I I I I I I I I I I I I I I I 1 I I I I I I I I I I 
Sbjct: 839 atgcctgtgacttttcacaacatcaggatttattggataacaacaaattccttgatagct 898 
Query: 1441 tgacaaggcaaacgcagaaacagactctttgattccaatcttacctatgaacattaactt 1500 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 899 tgacaaggcaaacgcagaaacagactctttgattccaatcttacctatgaacattaactt 958 
Query: 1501 tcagattatgcaccatatatcacacatacaatatatacatatacttacatgtacacatac 1560 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I i I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 959 tcagattatgcaccatatatcacacatacaatatatacatatacttacatgtacacatac 1018 
Query: 1561 atcatataatacaacatacacatatactatatacacatacacattcatagtcacatacat 1620 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 1019 atcatataatacagcatacacatatactatatacacatacacattcatagtcacatacat 1078 
Query: 1621 gtacatatacatcaatcatatacatgtatatgtacatatatcatatgcatatacatatgc 1680 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 1079 gtacatatacatcaatcatatacatgtatatgtacatatatcatatgcatatacatatgc 1138 
Query: 1681 atatacatatacgtactttacagactggctacatgggatt-gaagagtatgtaacagggc 1739 
i I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I i I I I I I I I I 
Sbjct: 1139 atatacatatacgtactttacagactggctacatgggattggaagagtatgtaacagggc 1198 
Query: 1740 tcagggaattgcaaagacacttgggaagcaggcagggtagctaaaggggtcaaaagggta 1799 
I I I I I I I I 1 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 1199 tcagggaattgcaaagacacttgggaagcaggcagggtagctaaaggggtcaaaagggta 1258 
Query: 1800 ataagataatcgctactggaggtctgctgctaagagtcaaggtttgagctgagccatggg 1859 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 1259 ataagataatcgctactggaggtctgctgctaagagtcaaggtttgagctgagccatggg 1318 
Query: 1860 cagaggctttagatgccaagtgcaggactcagtccagaaggcagttccatggcaagtaga 1919 
. I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 1319 cagaggctttagatgccaagtgcaggactcagtccagaaggcagttccatggcaagtaga 1378 
Query: 1920 gacagacagatgggcagctaagttgaagcccctgggaaggttgggctttctctgctacac 1979 
. I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 1379 gacagacagatgggcagctaagttgaagcccctgggaaggttgggctttctctgctacac 1438 
Query: 1980 acagggtggcaagataagggcttctcctcttcaatgggctcaggcgagagagccacatcc 2039 
, I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 1439 acagggtggcaagataagggcttctcctcttcaatgggctcaggcgagagagccacatcc 1498 
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Query: 2040 tttcccagtcttgttagtctagtgtgtcgtcactcctggtttgatattaacattggtgtg 2099 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 1499 tttcccagtcttgttagtctagtgtgtc-tcactcctggtttgatattaacattggtgtg 1557 
Query: 2100 tgtggctatagtccccccgccctgtttagtttgcttttttattttatatagtagggccct 2159 
I I I I I I I I I I I I I I I I I i I I I I I I I I I I I I I I i I I i I i I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 1558 tgtggctatagtccccccgccctgtttagtttgcttttttatttta-atagtagggccct 1616 
Query: 2160 ttctgctttaagagtaagttgttaatctgtctgtgccttgtgggtggtgctaggcagatg 2219 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 1617 ttctgctttaagagtaagttgttaatctgtctgtgccttgtgggtggtgcta-gcaaatg 1675 
Query: 2220 gtgtttatgtgcccatcaaggtgtgaattctacttctgcattttcactttaaatggaacc 2279 
1 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 167 6 gtgtttatgtgcccatcaaggtgtgaattctacttctgcattttcactttaaatggaacc 1735 
Query: 2280 aatgctgcttgtaaaatacaatcttggcagctcg-aagccattgtattgcacagtgtgga 2338 
I I I I I I I I I ! I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I i I I I I I I I I I I I I I I 
Sbjct: 1736 aatgctgcttgtaaaatacaatcttggcagctcgaaagccattgtattgcacagtgtgga 1795 
Query: 2339 gtaactcagagcagggcacatcctgatttcaatatctttatttttccactggatttgaat 2398 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 1796 gtaactcagagcagggcacatcctgatttcaatatctttatttttccactggatttgaat 1855 
Query: 2399 tgctagtgaggactcgaatctccatgcatagaagctgttagtctgaagtaagcttgtaca 2458 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 1 I I I I I I I I I I I I I I I I I I I I 
Sbjct: 1856 tgctagtgaggactcgaatctccatgcatagaagctgttagtctgaagtaagcttgtaca 1915 
Query: 2459 ctattgtctgagtt-agtatcagagtgattctggctcccgatgcagtggggaacgtattt 2517 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 1916 ctattgtctgagttgagtatcagagtgattctggctcccgatgcagtggggaacgtattt 1975 
Query: 2518 tcctttttcgtttctttctttcctttcctttcctttcctttcctttcctttcctttcctt 2577 
i i I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I i I I I I I I I I I I I I I I I I I I I I i I I 
Sbjct: 1976 tcctttttcgtttctttctttcctttcctttcctttcctttcctttcctttcctttcctt 2035 
Query: 2578 tcctttcctttcctttcctttcctttcctttcctttcctttcctttcctttcctttcctt 2 637 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 2036 tcctttcctttcctttcctttcctttcctttcctttcctttcctttcctttcctttcctt 2095 
Query: 2 638 tccttccttccatcctttcctttccttttattaaatctagaattgtcctcaaatattttg 2697 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 2096 tccttccttccatcctttcctttccttttattaaatctagaattgtcctcaaatattttg 2155 
Query: 2698 tgccattttgttttggcagtctgtttttatttttaaataaatgcagctcgagcaacgtgt 2757 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 2156 tgccattttgttttggcagtctgtttttatttttaaataaatgcagctcgagcaacgtgt 2215 
Query: 2758 aaactagaaggaactgataatcttttattttacaactctgaaattaaaccatgccatctg 2817 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 2216 aaactagaaggaactg—aatcttttattttacaactctgaaattaaaccatgccatctg 2273 
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Query: 2818 taatccacaacaaaggcatcacattttgagtcagccacagtaaagacaagggagttccct 2877 
I I I I I I I I I I I I I I 1 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 2274 taatccacaacaaaggcatcacattttgagtcagccacagtaaagacaagggagttccct 2333 
Query: 2878 aaatcacccttaaaagttttccaagcttcttcttcttcttttttttttttttctttccta 2937 
I 1 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I Sbjct: 2334 aaatcacccttaaaagttttccaagcttcttcttcttcttttttttttttttcttt-cta 2392 
Query: 2938 agtggagcatttatcttggagtcagttcatgtggccttatgcccacctccctccatcttc 2997 
I I I I I I I I I I I I I I I I I I I I I 1 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 2393 agtggagcatttatcttggagtcagttcatgtgg-cttatgcccacatccctccatcttc 2451 
Query: 2998 aacacttcaagctgggatgagggagtcaggaccagctgagcttggatctggaaggcgaca 3057 
I I I I I I I I I I I I I I I i I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 2452 aacacttcaag-tgggatgagggagtcagga-cagctgagcttggatctggaacgggaca 2509 
Query: 3058 ctgggtgactggcagcagggaaggcgccgtcagaaactagagagggagcgggttggacag 3117 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 2510 ct-ggtgagtgacaacgaggaaggcgccgtcagaaactagagagggagcgggttggacag 2568 
Query: 3118 agggtctcagggcggggcgggggaggagtgcaaagccgagcctgagggttggaacctgca 3177 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 2569 agggtctcagggcggggcgggggaggagtgcaaagccgagcctgagggttggaacctgca 2 62 8 
Query: 3178 gagcagcgacgccccctaggctataaatatggaagtgcctagctgctgacctccaggcag 3237 
I I I I I 1 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 2 629 gagcagcgacgccccctaggctataaatatggaagtgcctagctgctgacctccaggcag 2688 
Query: 3238 ttgggagggactggatgatgctgtcccgctggagaggattcgtggcttgagtcctgttcc 3297 
I I 1 I I I I I I I I I I i I I I 1 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 2 68 9 ttgggagggactggatgatgctgtcccgctggagaggattcgtggcttgagtcctgttcc 2748 
Query: 3298 accc 3301 
I I I I 
Sbjct: 2749 accc 2752 
Figure 4.2 Alignment results of 2.8 kb PCR fragment sequence (Sbjct) with cloned 
ATiA receptor promoter sequence (Query) in GenBank with accession no. s66402 by 
using M H Blast Search 2.0. 
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The first strategy is to clone the 3.2 kb ATiA receptor promoter into a pSEAP2-
Basic vector (5.8 kb) by using directional cloning. However, the cloning was 
unsuccessful and this may be due to the unsuccessful enzyme digestion ofMlu I 
and Bgl II in the 3.2 kb PCR fragment. To avoid the problem of inefficient 
enzyme digestion in both ends of the 3.2 kb PCR fragment, the PCR fragment 
was first cloned into a vector (pBluescript® II KS; 2.8 kb) with white blue 
screening properties by using blunt end ligation. The strategy is that after 
successful cloning, the 3.2 kb PCR insert will then be cut out by digested with 
Mlu I and Bgl II restriction endonuclease. Afterwards, the PCR fragment with 
two sticky ends of Mlu I and BglI I was then used to clone into the pSEAP2-
Basic vector. However, it is possible that the 3.2 kb PCR insert was larger then 
that of the vector (2.8 kb), the ligation efficiency was very low and no 
successful clone was isolated. 
In another approach, a larger vector (pOPRSWMCS operators; 5.8 kb) was 
used instead of the using pBluescript® II SK vector. This vector 
(pOPRSVIMCS operator) did not have the white blue screening properties. 
The 3.2 kb PCR insert was attempted to clone into the (pOPRSVL^CS 
operator) vector by using blunt end ligation. Though, the plasmid vector has 
larger molecular size than that of the pBluescript® H SK vector, no successful 
positive clone was detected. 
To evaluate whether smaller fragment will be easier to clone into vectors, 2.8 kb 
PCR fragment of ATiA receptor promoter was amplified with the 500 bp deleted 
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Chanter 5 
from the 5, end that of3.2 kb PCR fragment (Figure 4.1 lane2). All the methods 
and cloning vectors mentioned for 3.2 kb PCR fragment was repeated for the 
2.8 kb PCR fragment. Sequencing result of the 2.8 kb PCR fragment Is shown 
in Figure 4.2. Even the PCR insert fragment was 500 bp smaller than that of the 
3.3 kb PCR fragment, cloning of the 2.8 kb PCR fragment was still 
unsuccessful. 
To facilitate cloning, the 3.2 kb PCR fragment was divided into two fragment 
sizes. The strategy of dividing the 3.2 kb fragment into 1.4 kb and 2.2 kb PCR 
fragments is shown in Figure 4.3. The strategy is that after the 1.4 kb PCR 
fragment (Figure 4.4) cloned into pSESAP2-Basic vector and then the 2.2 kb 
PCR fragment (Figure 4.5) will then be jointed to the cloned 1.4 kb PCR 
fragment. All the methods and cloning vectors as mentioned for 3.2 and 2.8 kb 
PCR fragment were repeated for thel.4 kb PCR fragment. There was again no 
successful positive clone was detected. The 1.4 kb PCR fragment was attempted 
to clone into other cloning vectors (PCR-TRAP Cloning System and PCR 
Cloning kit). However, no positive clone was detected. As all the method of 
cloning the PCR fragments of ATiA receptor promoter into plasmid vector was 
not successful, library screening was performed. 
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PCR of 1.4 kb PCR fragment of 
ATla receptor promoter 
PacI 
M1UI. ^ < ^ r T>TT 
^ ^ - ^ ^ J ^ j T ^ EcoRV 
， PCR amplification of 2.2 kb 
ATla receptor promoter 
Blunt end ligation o f l . 4 kb PCR fragment 
into plasmid vector (pCAps) PacI " ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ BglII 
V 
Z PacI V 
M l u ^ f < ^ EcoRV 
C ^ ^ ~ pCAPS ^ ^ ^ 2.2 kb PCR fragment digested with PacI 
PacI BglII 
V . ^ ^ ^ m i ^ ^ m ^ ^ 
Positive clone digested with PacI and EcoRV 
M l u I � PacI EcoRV jy ^ / 
Ligation tojoint the two fragment 
M l u I ^ PacI PacI y B g l l l 
——E=^—= 叫 - - ^ H ^ ^ 1 ^ ^ ^ M ^ 0  
EcoRV 
” 
M l u I j ^ ^ _ _ ^ ^ ^ ^ ^ ^ ^ BglII 
c i ^ ^ ^ ^ ^ ^ " ^ ^ ^ r i ^ ^ ^ ^ ^ ^ 
Figure 4.3 Schematic diagram of cloning 1.4 and 2.2 kb PCR fragment of 
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Figure 4.4 1.4 kb PCR fragment (lane 1) of ATj^ receptor 
promoter was obtained by PCR method. 1 kb DNA markers 
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Figure 4.5 2.2 kb PCR fragment (lane 1) ofAT!A receptor promoter 
was obtained by PCR method. 1 kb DNA markers were shown on lane M. 
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4.3.2 Library Screening of ATiA Receptor Promoter 
For library screening, the 2.2 kb PCR fragment was used as probe, and 
sequencing result of the 2.2 kb fragment is shown in Figure 4.6. There was only 
9 nucleotides mismatch in 2.2 kb sequences when compared to the cloned ATiA 
receptor promoter in GenBank with an accession no. S66402. 
The library screening method is shown in Figure 4.7. A bacteriophage P1 rat 
genomic library was firstly screened by PCR with ATiA receptor primers F1 and 
R1 as mentioned in section 3.2.5.1 and then the positive clones were further 
probed with the sequenced 2.2 kb PCR fragment of ATiA receptor promoter. 
From the P1 rat genomic library, three positive clones were obtained. (Library 
screening was performed by GenomeSystemsInc.) 
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Query: 1426 aattccttgatagcttgacaaggcaaacgcagaaacagactctttgattccaatcttacc 1485 
I I I I I I I I I 1 I I I I I 1 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 1 aattccttgatagcttgacaaggcaaacgcagaaacagactctttgattccaatcttacc 60 
Query: 1486 tatgaacattaactttcagattatgcaccatatatcacacatacaatatatacatatact 1545 
I I I I I I I I I I I I I I I I I I I I I I I i I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 61 tatgaacattaactttcagattatgcaccatatatcacacatacaatatatacatatact 120 
Query: 1546 tacatgtacacatacatcatataatacaacatacacatatactatatacacatacacatt 1605 
I I I I I 1 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 121 tacatgtacacatacatcatataatacaacatacacatatactatatacacatacacatt 180 
Query: 1606 catagtcacatacatgtacatatacatcaatcatatacatgtatatgtacatatatcata 1665 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 181 catagtcacatacatgtacatatacatcaatcatatacatgtatatgtacatatatcata 240 
Query: 1666 tgcatatacatatgcatatacatatacgtactttacagactggctacatgggattgaaga 1725 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 1 I I I I I I I I I I I I Sbjct: 241 tgcatatacatatgcatatacatatacgtactttacagactggctacatgggattgaaga 300 Query: 172 6 gtatgtaacagggctcagggaattgcaaagacacttgggaagcaggcagggtagctaaag 1785 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 301 gtatgtaacagggctcagggaattgcaaagacacttgggaagcaggcagggtagctaaag 360 Query: 178 6 gggtcaaaagggtaataagataatcgctactggaggtctgctgctaagagtcaaggtttg 1845 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 361 gggtcaaaagggtaataagataatcgctactggaggtctgctgctaagagtcaaggtttg 420 
Query: 1846 agctgagccatgggcagaggctttagatgccaagtgcaggactcagtccagaaggcagtt 1905 
I I I 1 I I I I I I I I I I I I I I I I I I I I I I I I 1 I I I I I I I 1 I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 421 agctgagccatgggcagaggctttagatgccaagtgcaggactcagtccagaaggcagtt 480 
Query: 1906 ccatggcaagtagagacagacagatgggcagctaagttgaagcccctgggaaggttgggc 1965 
I I 1 I I I I I i I I I I I 1 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 481 ccatggcaagtagagacagacagatgggcagctaagttgaagcccctgggaaggttgggc 540 
Query: 1966 tttctctgctacacacagggtggcaagataagggcttctcctcttcaatgggctcaggcg 2025 
I I I I I I I I 1 I I I I I I i I I I I I I I I I I I I i I 1 I I i I I I I I I I I I I i I I I I 1 I I I I I I I I I I 
Sbjct: 541 tttctctgctacacacagggtggcaagataagggcttctcctcttcaatgggctcaggcg 600 
Query: 2026 agagagccacatcctttcccagtcttgttagtctagtgtgtcgtcactcctggtttgata 2085 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 601 agagagccacatcctttccca-tcttgttagtctagtgtgtcgtcactcctggtttgata 659 
Query: 2086 ttaacattggtgtgtgtggctatagtccccccgccctgtttagtttgcttttttatttta 2145 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 660 ttaacattggtgtgtgtggctatagtccccccgccctgtttagtttgcttttttatttta 719 
Query: 2146 tatagtagggccctttctgctttaagagtaagttgttaatctgtctgtgccttgtgggtg 2205 
1 I 1 1 I I I I I I I I I I I I I 1 I I 1 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 720 tatagtagggccctttctgctttaagagtaagttgttaatctgtctgtgccttgtgggtg 779 
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Query: 2206 gtgctaggcagatggtgtttatgtgcccatcaaggtgtgaattctacttctgcattttca 2265 
I I I I I I I I I I I I I I I I I I I I I 1 I 1 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 780 gtgctaggcagatggtgtttatgtgcccatcaaggtgtgaattctacttctgcattttca 839 
Query: 2266 ctttaaatggaaccaatgctgcttgtaaaatacaatcttggcagctcg-aagccattgta 2324 
I I I 1 I I 1 I I I I I I 1 I I I I I I I I I I I I I I I 1 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 840 ctttaaatggaaccaatgctgcttgtaaaatacaatcttggcagctcgaaagccattgta 899 
Query: 2325 ttgcacagtgtggagtaactcagagcagggcacatcctgatttcaatatctttatttttc 2384 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I 1 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 900 ttgcacagtgtggagtaactcagagcagggcacatcctgatttcaatatctttatttttc 959 
Query: 2385 cactggatttgaattgctagtgaggactcgaatctccatgcatagaagctgttagtctga 2 44 4 
I I I I I I I I I I I 1 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 960 cactggatttgaattgctagtgaggactcgaatctccatgcatagaagctgttagtctga 1019 
Query: 2445 agtaagcttgtacactattgtctgagttagtatcagagtgattctggctcccgatgcagt 2504 
I I I I 1 I 1 I I 1 I I I I 1 I I I I I 1 1 I I I I I I I 1 I I I I I I I I 1 I 1 I I I I I I I I 1 1 I I I I I I 1 I 1 Sbjct: 1020 agtaagcttgtacactattgtctgagttagtatcagagtgattctggctcccgatgcagt 1079 Query: 2505 ggggaacgtattttcctttttcgtttctttctttcctttcctttcctttcctttcctttc 2564 I I I I I I 1 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 1080 ggggaacgtattttcctttttcgtttctttctttcctttcctttcctttcctttcctttc 1139 Query: 2565 ctttcctttcctttcctttcctttcctttcctttcctttcctttcctttcctttcctttc 2624 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 1140 ctttcctttcctttcctttcctttcctttcctttcctttcctttcctttcctttcc-ttc 1198 
Query: 2 625 ctttcctttcctttccttccttccatcctttcctttccttttattaaatctagaattgtc 2684 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 1199 ctttcctttcctttccttccttccatcctttcctttccttttattaaatctagaattgtc 1258 
Query: 2685 ctcaaatattttgtgccattttgttttggcagtctgtttttatttttaaataaatgcagc 2744 
I I I I I 1 I I 1 I I I 1 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 1259 ctcaaatattttgtgccattttgttttggcagtctgtttttatttttaaataaatgcagc 1318 
Query: 2745 tcgagcaacgtgtaaactagaaggaactgataatcttttattttacaactctgaaattaa 2804 
I I I I I I 1 1 I I I I 1 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 1319 tcgagcaacgtgtaaactagaaggaactgataatcttttattttacaactctgaaattaa 1378 
Query: 2805 accatgccatctgtaatccacaacaaaggcatcacattttgagtcagccacagtaaagac 2864 
I I I I I I I I I I I I I I 1 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 1379 accatgccatctgtaatccacaacaaaggcatcacattttgagtcagccacagtaaagac 1438 
Query: 2865 aagggagttccctaaatcacccttaaaagttttccaagcttcttcttcttcttttttttt 2924 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 1439 aagggagttccctaaatcacccttaaaagttttccaagcttcttcttcttcttttttttt 1498 
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Query: 2925 tttttctttcctaagtggagcatttatcttggagtcagttcatgtggccttatgcccacc 2984 
I I I I I I I I I I I I 1 I I I I 1 1 1 I I I I 1 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 1499 tttttcttt-ctaagtggagcattaatcttggagtcagttcatgtggccttatgcccacc 1557 
Query: 2985 tccctccatcttcaacacttcaagctgggatgagggagtcaggaccagctgagcttggat 3044 
I I I I I I I 1 I 1 I I I I 1 I I I 1 I 1 I 1 I 1 I I I 1 I 1 I I 1 I I I I I I I I I I I I I I I I I I I I I ,l I I I I 
Sbjct: 1558 tccctccatcttcaacacttcaagctgggatgagggagtcaggaccagctgagcttggat 1617 
Query: 3045 ctggaaggcgacactgggtgactggcagcagggaaggcgccgtcagaaactagagaggga 3104 
1 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I Sbjct: 1618 ctggaaggcgacactgggtgactggcagcagggaaggcgccgtcagaaactagagaggga 1677 Query: 3105 gcgggttggacagagggtctcagggcggggcgggggaggagtgcaaagccgagcctgagg 3164 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 1678 gcgggttggacagagggtctcagggcggggcgggggaggagtgcaaagccgagcctgagg 1737 
Query: 3165 gttggaacctgcagagcagcgacgccccctaggctataaatatggaagtgcctagctgct 3224 
I I I I I I I I I I I I I I I I I I I I I I I 1 I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 1738 gttggaacctgcagagcagcgacgccccctaggctataaatatggaagtgcatagctgct 1797 
Query: 3225 gacctccaggcagttgggagggactggatgatgctgtcccgctggagaggattcgtggct 3284 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
Sbjct: 1798 gacctccaggcagttgggagggactggatgatgctgtccngctggagatgnntcntggcn 1857 
Query: 3285 tgagtcct 3292 
I I I I I I I I 
Sbjct: 1858 tgagtcct 1865 
Figure 4.6Alignment of2.2 kb PCR fragment sequences (Sbjct) with cloned ATiA receptor 
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Various PCR fragments of ATiA receptor promoter has been obtained by using 
PCR method. However, the PCR fragment of ATiA receptor promoter has not 
been successfully cloned into plasmid vectors. It is possible that the insert 
fragments were too large to be ligated with the plasmid vector, or the 
vector/insert is self-ligation. Also, possibility cannot be excluded that there was 
not enough amount ofDNA used to perform ligation and transformation. 
Sequence data of the 2.2 kb PCR fragment of ATiA receptor promoter show that 
it has only 9 nucleotides mismatch. Therefore, the 2.2 kb PCR fragment was 
used as a probe to screen for the P1 rat genomic library. The three positive 
clones of ATiA receptor promoter obtained from GenomeSystemsInc was first 
screened by using PCR amplification of ATiA receptor. In second round of 
screening, positive clones were probed with the 2.2 kb PCR fragment. The 
positive clones obtained from second round screening will then performed with 
restriction mapping and probed with the 2.2 kb PCR fragment. Fragment 
containing the ATiA receptor promoter will be cloned into the pSEAP2-Basic 
vector for promoter activity assay. 
130 
Chanter 5 
Chapter 5 General Discussions 
Rearrangement of Mas DNA was found in MH3T3 transformants which 
were transfected with DNA from human epidermoid carcinoma, human acute 
myelocytic leukemia and human ovarian carcinoma. Results from the rat 
pancretoma AR4-2J cells have shown that though the Mas oncogene encodes 
the same amino acid sequences of the cloned Mas (Young et al., 1998) there 
was no DNA rearrangement in the 5' upstream region. The mechanism of 
how the Mas oncogene is activated on AR4-2J cells is an open question. 
Results from stable transfected Mas oncogene into MH3T3 cells suggested 
that the expression of the Mas oncogene leads to an increase in the 
expression of the angiotensin receptor ATi. It is well known that angiotensin 
II is a major octapeptide which take part in the renin-angiotensin system 
(RAS). Angiotensin II is a powerful vasoconstrictive agents acting on 
arteriola smooth muscle cells. It participates in the regulation of blood 
pressure by facilitating immediate re-establishment of blood pressure in 
emergency situations or by maintaining blood pressure under more chronic 
conditions. The vasoconstrictive effects of angiotensin II relates to its effect 
on blood volume regulation. Also, angiotensin is the major regulator of 
aldosterone secretion. Indeed, prolonged infusion of angiotensin induces in 
human hypertension with a positive sodium balance resulting from secondary 
hyperaldosteronism. If Mas oncogene is present in cancer patient, then he 
may result from hypertension as expression ofMas oncogene can enhance 
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the expression of angiotensin 11 but further investigation is required. 
Wolf and co-workers (1992) showed that over expression of Mas oncogene 
in proximal tubular cells can modulate tubular cell phenotype toward 
proliferation rather than hypertrophy. Moreover, the change in phenotype of 
proximal tubular cells is due to failure of angiotensin II to stimulate 
induction ofTGF_pi protein in Mas over expressed cells. Therefore, over 
expression of Mas oncogene may modulate the growth promoting effect of 
angiotensin II by driving the cell to divide rather than to increase in cell size. 
If that is true, oncogenic effect of Mas may indirectly mediate via the 
angiotensin receptor. The possibility remains to be addressed in the future. 
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APPENDK 1 Composition of Solutions 
5 X ligation Buffer 
250 mM Tris-HCl, pH 7.6; 
50mMMgC12; 
5 mM ATP; 
5mMDTT; 
25% (w/v) polyethylene glycol-8000 
lOxPCRBuffer 
200 mM Tris-HCl, pH 8.4; 
500mMKCl 
10X Tris-base Buffer 
891.5mMTris base; 
889.5 mM Boric acid; 
25mMEDTA, pH8.3 
20 X SSC Stock Solution 
3 MNaCl; 
0.3 M sodium citrate, pH 7; 
autoclaved 
6X DNA Loading Buffer 
0.25 % w/v bromophenol blue; 





Dilute Blocking Reagent stock solution 
1:10 with Maleic acid buffer 
Buffer 3 
O.lMTris HC1, pH9.5; 
0.05MMgCl2; 
O.lMNaCl; 
2 mM levamisole; 
1.875 mgBOT; 
5 mgNBT 
(for 10 ml) 
Buffer P1 (Resuspension Buffer) 
50 mM Tris.Cl, pH 8.0; 
lOmMEDTA; 
100 ^ig/ml RNase A 
Buffer P2 (Lysis Buffer) 
200mMNaOH; 
1% SDS 
Buffer P3 (Neutralization Buffer) 
3.0 M potassium acetate, pH 5.5 
Buffer QBT (Equilibration Buffer) 
750mMNaCl; 
50mMMOPS, pH 7.0; 








Buffer QF (Elution Buffer) 
1.25MNaCl; 
50 mM Tris, Tris.Cl, pH8.5; 
15% isopropanol 
Cell Lysis Solution 
0.2MNaOH; 
1 % SDS 
Cell Resuspension Solution 
50 mM Tris-HCl, pH7.5; 
lOmMEDTA; 
100 ^ig/ml RNase A 
Column Wash Solution 
200mMNaCl; 




Denaturation Solution 1 
0.5MNaOH; 
1.5MNaCl 







100 mM Tris-HCl, pH 9.5; 
lOOmMNaCl 
DNA Sequencing Gel 
7 M urea; 
5 % polyacrylamide; 
l X T B E 
Elution Buffer EB 
lOmMTris.Cl, pH8.5 
Homogenization Buffer 





1 mM Benzamide; 
1 mMNa3VO4 
Immuno-blotting Buffer n 
25 g Skimmed milk; 
0.1 gNaN3; 
4.38gNaCl; 
(g /500 ml) 
LB Agar 
10 gfL Tryptone; 
5 g i Yeast extract; 
lOg/LNaCl; 
15 gfL Bactroagar 
Sterilize by autoclaving for 15 min at 121 °C 
Luria-Bertani (LB) Medium 
10 gfh Tryptone; 
5 %fL Yeast extract; 
lOg/LNaCl 
Sterilize by autoclaving for 15 min at 121 ^ C 
Maleic Acid Buffer 







Neutralization Solution 1 
0.5 M Tris-HCL, pH7.5; 
3MNaCl 
Neutralization Solution 2 
1 M Tris-HCl, pH 7.5; 
1.5MNaCl 
Reagent A 
Alkaline copper tartrate solution 
ReagentB 
Ascorbic acid; 
Bathocuproine disulfonic solution 
Reservoir Buffer 10X 
30.2 g Tris base; 
144 g glycine; 
lL ddH2O 
Running Buffer 
80 ml 10X reservoir buffer; 
8 ml 10% SDS; 
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712 ml ddH2O 
Sample Buffer 2X 
20 ml 4X stacking gel buffer; 
16 ml glycerol; 
32 ml 10% SDS; 
2 mg bromophenol blue; 
0.8 ml P-mercaptoethanol； 
11 ml ddH2O 
SDS Stock Solution 
lO%(w/v)inH2O 
filtered through a 0.2 - 0.455 |Lim membrane 
Separating Gel Buffer 4X 
182 g Tris base; 
lL ddH2O 
Solution A 
2 0/0 Na2CO3; 
1 % CuSO4; 
1 0/0 KNa tartrate 
Stacking Gel Buffer 4X 




Stock Gel Solution 
\ 
150 g acrylamide; 
4 g Bis; 
lL ddH2O 
TE Buffer 
lOmMTris.Cl, pH 8.0; 
1 mMEDTA 
Transfer protein-blot Buffer 
20 ml 10X reservoir bufFer; 
40 ml methanol; 
140 ml ddH2O 
Washing Buffer 
100 mM maleic acid, pH 7.5; 
150mMNaCl; 




#2490 Expression of mas oncogene in pancreatoma AR4-2J cells. Tang, 
W.M., Lee. M.W., Tsang, D.S.C., Lee, S.ST, and Cheung, W.T. Department of 
Biochemistry, The Chinese University of Hong Kong, Hong Kong, China. 
This study is part of an effort to unravel the role of mas oncogene in regulating 
cellular angiotensin response. Mas oncogene was originally isolated from the 
human epidermoid carcinoma using a tumorigenicity assay. Sequence analysis 
indicates that mas oncogene is a membrane protein with seven putative trans-
membrane segments and a calculated molecular mass of 37 KDa. Transfection 
studies indicate that mas oncogene erther endows an angiotensin response or 
potentiates the endogenous angiotensin response in transfected cells. However, 
mas oncogene shares less than 10% of overall sequence identity with that of 
cloned angiotensin receptor. Over-expression of mas oncogene has been shown 
to stimulates the mitogen-activated protein kinase cascade and leading to an 
increased expression of various genes, such as cyclin, which regulate cellular 
growth and proliferation. Previously, we have reported the expression of a func-
• tional ATiA angiotensin receptor in pancreatoma AR'4-2J cells. The possibility of 
co-expression of mas oncogene in AR4-2J cells was subsequently confirmed by 
RT-PCR. Sequence analysis of the RT-PCR fragment indicates two substitutions 
of nucleotide in the encoding sequences of mas oncogene, but the change did 
not alter the amino acid sequence. In contrast to previous finding that there was 
an upstream 5' rearrangement of mas oncogene in various cancer cells, Southern 
analysis of mas oncogene did not reveal any genomic rearrangement in AR4-2J 
cells. Expression of mas oncoprotein was further confirmed by Western blot study 
with a polyclonal antibody against a peptide which is derived from the putative 
C-terminus of mas oncogene. Two specific immunoreactive bands were identified 
with molecular mass of 48 and 74 KDa, suggesting that the mas oncoprotein 
might be glycosylated. The co-expression of mas oncogene and angiotensin 
receptor in various models suggests a possibility that mas oncogene enhances 
cellular angiotensin response either by up-regulating the expression of angioten-
sin receptor, or by phosphorylation modification of angiotensin receptors. 
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